

levels in the NAc through potentiation of plasmalemmal and vesicular DA uptake *via* induction of TNF- $\alpha$  expression (Fig. 7), although the mechanism by which TNF- $\alpha$  is regulated by shati remains to be elucidated.

Motif analyses have revealed that shati contains sequences of GNAT (Niwa *et al.* 2007a). Docking simulations with acetyl-CoA or ATP conducted using Molecular Operating Environment software reveal possible acetyl-CoA- and/or ATP-binding sites, since there is low potential energy for these interactions, in contrast with the prohibitively high energy of docking with DA, DNA or nuclear localization signals (Niwa *et al.* 2007a). These results suggest shati to have a physiological role in producing acetylcholine or the metabolic action of ATP. Accordingly, we have to investigate the mechanism by which shati regulates the production of acetylcholine or metabolic roles of ATP in subsequent studies.

In conclusion, we hypothesized that TNF- $\alpha$  expression induced by shati inhibits the METH-induced increase in extracellular DA levels in the NAc by promoting DA uptake and finally inhibits sensitization to and the rewarding effects of METH (Fig. 7). Targeting the shati-TNF- $\alpha$  system would provide a new therapeutic approach to the treatment of METH dependence.

## Acknowledgments

This study was supported in part by Research Fellowships of the Japan Society for the Promotion of Science (JSPS) for Young Scientists; by Grants-in-aid for Scientific Research (B) and for Exploratory Research from the JSPS; by the 'Academic Frontier' Project for Private Universities (2007–2011) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; by the International Research Project supported by the Meijo Asian Research Center (MARC); by Health and Labour Sciences Research on Regulatory Science of Pharmaceuticals and Medical Devices from the Ministry of Health, Labour and Welfare, Japan; by Research on Risk of Chemical Substances, Health and Labour Science Research Grants supported by the Ministry of Health, Labour and Welfare; by the Japan France Joint Health Research Program; and by the Uehara Foundation.

The authors are grateful to the Riken Cell Bank for the pheochromocytoma-12 (PC12) cells, and to Mrs. Nobuyoshi Hamada and Yoshiyuki Nakamura, Radioisotope Center Medical Branch, Nagoya University Graduate School of Medicine, for technical assistance.

## References

Amara S. G. and Kuhar M. J. (1993) Neurotransmitter transporters: recent progress. *Annu. Rev. Neurosci.* **16**, 73–93.  
 Barone F. C., Arvin B., White R. F., Miller A., Webb C. L., Willette R. N., Lysko P. G. and Feuerstein G. Z. (1997) TNF- $\alpha$ . A mediator of focal ischemic brain injury. *Stroke* **28**, 1233–1244.  
 Baud V. and Karin K. (2001) Signal transduction by tumor necrosis factor and its relatives. *Trends Cell Biol.* **11**, 372–377. Review.

Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y. and Hirsch E. C. (1994) Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. *Neurosci. Lett.* **172**, 151–154.  
 Cen X., Nitta A., Ibi D., Zhao Y., Niwa M., Taguchi K., Hamada M., Ito Y., Ito Y., Wang L. and Nabeshima T. (2008) Identification of piccolo as a regulator of behavioral plasticity and dopamine transporter internalization. *Mol. Psychiatry* **13**, 451–463.  
 Chen N. H., Reith M. E. and Quick M. W. (2004) Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. *Pflugers Arch.* **447**, 519–531. Review.  
 Devin A., Lin Y. and Liu Z. G. (2003) The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases. *EMBO* **4**, 623–627.  
 Finberg J. P. and Youdim M. B. (1983) Selective MAO A and B inhibitors: their mechanism of action and pharmacology. *Neuropharmacology* **22**, 441–446. Review.  
 Fog J. U., Khoshbouei H., Holy M. *et al.* (2006) Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. *Neuron* **51**, 417–429.  
 Fornai F., Lenzi P., Lazzeri G., Ferrucci M., Fulceri F., Giorgi F. S., Falleni A., Ruggieri S. and Paparelli A. (2007) Fine ultrastructure and biochemistry of PC12 cells: a comparative approach to understand neurotoxicity. *Brain Res.* **1129**, 174–190.  
 Franklin K. B. J. and Paxinos G. (1997) *The Mouse Brain: In Stereotaxic Coordinates*. Academic Press, San Diego.  
 Grace A. A. (1995) The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. *Drug Alcohol Depend.* **37**, 111–129. Review.  
 Greene L. A. and Rein G. (1978) Short-term regulation of catecholamine biosynthesis in a nerve growth factor responsive clonal line of rat pheochromocytoma cells. *J. Neurochem.* **30**, 549–555.  
 Guha M., Bai W., Nadler J. L. and Natarajan R. (2000) Molecular mechanisms of tumor necrosis factor  $\alpha$  gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. *J. Biol. Chem.* **275**, 17728–17739.  
 Horn A. S. (1990) Dopamine uptake: a review of progress in the last decade. *Prog. Neurobiol.* **34**, 387–400. review.  
 Hsu H., Xiong J. and Goeddel D. V. (1995) The TNF receptor 1-associated protein TRADD signals cell death and NF- $\kappa$ B activation. *Cell* **81**, 495–504.  
 Hyman S. E. (1996) Addiction to cocaine and amphetamine. *Neuron* **16**, 901–904.  
 Jones S. R., Gainetdinov R. R., Jaber M., Giros B., Wightman R. M. and Caron M. G. (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. *Proc. Natl Acad. Sci. USA* **95**, 4029–4034.  
 Koob G. F. (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. *Trends Pharmacol. Sci.* **13**, 177–184.  
 Koob G. F., Sanna P. P. and Bloom F. E. (1998) Neuroscience of addiction. *Neuron* **21**, 467–476.  
 Loder M. K. and Melikian H. E. (2003) The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. *J. Biol. Chem.* **278**, 22168–22174.  
 Maier S. F. and Watkins L. R. (1998) Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. *Psychol. Rev.* **105**, 83–107.  
 Markey K. A., Kondo H., Shenkman L. and Goldstein M. (1980) Purification and characterization of tyrosine hydroxylase from a clonal pheochromocytoma cell line. *Mol. Pharmacol.* **17**, 79–85.

- Melikian H. E. and Buckley K. M. (1999) Membrane trafficking regulates the activity of the human dopamine transporter. *J. Neurosci.* **19**, 7699–7710.
- Morón J. A., Zakharova I., Ferrer J. V. *et al.* (2003) Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. *J. Neurosci.* **23**, 8480–8488.
- Nakajima A., Yamada K., Nagai T. *et al.* (2004) Role of tumor necrosis factor- $\alpha$  in methamphetamine-induced drug dependence and neurotoxicity. *J. Neurosci.* **24**, 2212–2225.
- Nestler E. J. (2001) Molecular basis of long-term plasticity underlying addiction. *Nat. Rev. Neurosci.* **2**, 119–128.
- Niwa M., Nitta A., Mizoguchi H., Ito Y., Noda Y., Nagai T. and Nabeshima T. (2007a) A novel molecule 'shati' is involved in methamphetamine-induced hyperlocomotion, sensitization, and conditioned place preference. *J. Neurosci.* **27**, 7604–7615.
- Niwa M., Nitta A., Shen L., Noda Y. and Nabeshima T. (2007b) Involvement of glial cell line-derived neurotrophic factor in inhibitory effects of a hydrophobic dipeptide Leu-Ile on morphine-induced sensitization and rewarding effects. *Behav. Brain Res.* **179**, 167–171.
- Niwa M., Nitta A., Yamada K. and Nabeshima T. (2007c) The roles of glial cell line-derived neurotrophic factor, tumor necrosis factor- $\alpha$ , and an inducer of these factors in drug dependence. *J. Pharmacol. Sci.* **104**, 116–121.
- Niwa M., Nitta A., Yamada Y., Nakajima A., Saito K., Seishima M., Noda Y. and Nabeshima T. (2007d) Tumor necrosis factor- $\alpha$  and its inducer inhibit morphine-induced rewarding effects and sensitization. *Biol. Psychiatry* **62**, 658–668.
- Niwa M., Nitta A., Yamada Y., Nakajima A., Saito K., Seishima M., Shen L., Noda Y., Furukawa S. and Nabeshima T. (2007e) An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor- $\alpha$  protects against methamphetamine-induced rewarding effects and sensitization. *Biol. Psychiatry* **61**, 890–901.
- Niwa M., Yan Y. and Nabeshima T. (2008) Genes and molecules that can potentiate or attenuate psychostimulant dependence: relevance of data from animal models to human addiction. *Ann. NY Acad. Sci.* **1141**, 76–95.
- Rahman I. and MacNee W. (2000) Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. *Free Radic. Biol. Med.* **28**, 1405–1420.
- Rawson R. A., Gonzales R. and Brethen P. (2002) Treatment of methamphetamine use disorders: an update. *J. Subst. Abuse Treat.* **23**, 145–150. Review.
- Roda L. G., Nolan J. A., Kim S. U. and Hogue-Angcletti R. A. (1980) Isolation and characterization of chromaffin granules from a pheochromocytoma (PC 12) cell line. *Exp. Cell Res.* **128**, 103–109.
- Sampath D., Jackson G. R., Werrbach-Perez K. and Perez-Polo J. R. (1994) Effects of nerve growth factor on glutathione peroxidase and catalase in PC12 cells. *J. Neurochem.* **62**, 2476–2479.
- Self D. W. and Nestler E. J. (1995) Molecular mechanisms of drug reinforcement and addiction. *Annu. Rev. Neurosci.* **18**, 463–495. Review.
- Sulzer D., Sonders M. S., Poulsen N. W. and Galli A. (2005) Mechanisms of neurotransmitter release by amphetamines: a review. *Prog. Neurobiol.* **75**, 406–433.
- Tischler A. S. (2002) Chromaffin cells as models of endocrine cells and neurons. *Ann. NY Acad. Sci.* **971**, 366–370. Review.
- Torres G. E., Gainetdinov R. R. and Caron M. G. (2003) Plasma membrane monoamine transporters: structure, regulation and function. *Nat. Rev. Neurosci.* **4**, 13–25. Review.
- Vaccaro K. K., Liang B. T., Perelle B. A. and Perlman R. L. (1980) Tyrosine 3-monooxygenase regulates catecholamine synthesis in pheochromocytoma cells. *J. Biol. Chem.* **255**, 6539–6541.
- Vassalli P. (1992) The pathophysiology of tumor necrosis factors. *Annu. Rev. Immunol.* **10**, 411–452. Review.
- van Vliet C., Bukczynska P. E., Puryer M. A., Sadek C. M., Shields B. J., Tremblay M. L. and Tiganis T. (2005) Selective regulation of tumor necrosis factor-induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase. *Nat. Immunol.* **6**, 253–260.
- Wada R., Tiffit C. J. and Proia R. L. (2000) Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. *Proc. Natl Acad. Sci. USA* **97**, 10954–10959.
- Wise R. A. (1996) Neurobiology of addiction. *Curr. Opin. Neurobiol.* **6**, 243–251.
- Youdim M. B. (1991) PC12 cells as a window for the differentiation of neural crest into adrenergic nerve ending and adrenal medulla. *J. Neural Transm. Suppl.* **34**, 61–67.



## Methamphetamine-induced hyperthermia and lethal toxicity: Role of the dopamine and serotonin transporters

Yohtaro Numachi<sup>a</sup>, Arihisa Ohara<sup>a</sup>, Motoyasu Yamashita<sup>a</sup>, Setsu Fukushima<sup>a</sup>,  
Hideaki Kobayashi<sup>a</sup>, Harumi Hata<sup>a</sup>, Hidekazu Watanabe<sup>a</sup>, F. Scott Hall<sup>b</sup>,  
Klaus-Peter Lesch<sup>c</sup>, Dennis L. Murphy<sup>d</sup>, George R. Uhl<sup>b</sup>, Ichiro Sora<sup>a,b,\*</sup>

<sup>a</sup> Department of Biological Psychiatry, Tohoku University Graduate School of Medicine, Japan

<sup>b</sup> Molecular Neurobiology Branch, National Institute on Drug Abuse, Division of Intramural Research, USA

<sup>c</sup> Department of Psychiatry, University of Wurzburg, Germany

<sup>d</sup> Laboratory of Clinical Science, National Institute of Mental Health, Division of Intramural Research Programs, USA

Received 1 February 2007; received in revised form 4 June 2007; accepted 7 June 2007

Available online 27 June 2007

### Abstract

We examined the hyperthermic and lethal toxic effects of methamphetamine in dopamine transporter (DAT) and/or serotonin transporter (SERT) knockout (KO) mice. Methamphetamine (45 mg/kg) caused significant hyperthermia even in the mice with a single DAT gene copy and no SERT copies (DAT<sup>+/-</sup> SERT<sup>-/-</sup> mice). Mice with no DAT copies and a single SERT gene copy (DAT<sup>-/-</sup> SERT<sup>+/-</sup> mice) showed significant but reduced hyperthermia when compared to wild-type mice after methamphetamine. Surprisingly, DAT/SERT double KO mice exhibited a paradoxical hypothermia after methamphetamine. These results demonstrate that methamphetamine exerts a hyperthermic effect via DAT, or via SERT, in the absence of DAT. The selective norepinephrine transporter blocker (20 mg/kg nisoxetine) caused hyperthermia in DAT/SERT double KO mice, suggesting that the norepinephrine system is not responsible for methamphetamine-induced paradoxical hypothermia in the double KO mice. DAT gene deletion in mice strikingly increased LD<sub>50</sub> of methamphetamine by 1.7–1.8 times that of wild-type mice, suggesting that the lethal toxic effect of methamphetamine is mainly dependent on DAT. Moreover, dissociation between hyperthermic and lethal toxic effects of methamphetamine in DAT single KO mice and DAT/SERT double KO mice suggest that hyperthermia is not a prerequisite for methamphetamine-induced lethality. Methamphetamine (45 mg/kg) significantly increased mRNA of interleukin-1 $\beta$ , which is the major endogenous pyrogen, in the hypothalamus of wild-type mice but not in DAT/SERT double KO mice, which provides a partial mechanism of methamphetamine-induced paradoxical hypothermia. These results suggest that DAT and SERT are key molecules for hyperthermic and lethal toxic effects of methamphetamine.

© 2007 Elsevier B.V. All rights reserved.

**Keywords:** Monoamine; Norepinephrine; Paradoxical hypothermia; Interleukin-1 $\beta$ ; Transgenic knockout mouse

### 1. Introduction

Methamphetamine is abused worldwide for its potent stimulant and euphoric effects (Sato et al., 1992; Hanson et al., 2004). Methamphetamine abuse causes serious health hazards including irreversible neuronal degeneration, seizures, hyperthermia and death in human and experimental animals (Davidson et al., 2001;

Kita et al., 2003; Chan et al., 1997). Among these side effects, methamphetamine produces hyperthermia and/or dopaminergic neurotoxicity in most species, although differences in age (Imam and Ali, 2001), sex (Wagner et al., 1993), ambient temperature (Ali et al., 1994; Miller and O'Callaghan, 2003; Namiki et al., 2005), dosing, and route of administration (Davidson et al., 2001) can influence these effects. Clinical reports and animal studies indicate that lethality by methamphetamine closely correlates with hyperthermia, which may be the primary cause of death (Bowyer et al., 1994; Davidson et al., 2001; Namiki et al., 2005). Methamphetamine enters the terminals/neuron via the monoamine transporters (dopamine transporter: DAT, serotonin transporter: SERT, or

\* Corresponding author. Department of Biological Psychiatry, Tohoku University Graduate School of Medicine 1-1 Seiryomachi, Sendai, 980-8574, Japan. Tel.: +81 22 717 7808; fax: +81 22 717 7809.

E-mail address: [isora@mail.tains.tohoku.ac.jp](mailto:isora@mail.tains.tohoku.ac.jp) (I. Sora).

norepinephrine transporter: NET), displaces both vesicular and intracellular monoamines and facilitates release of monoamines into the extraneuronal space by synaptic transport in the monoamine transporters (Seiden et al., 1993). Animal studies suggest that dopamine receptor activation is crucial for methamphetamine-induced hyperthermia (Funahashi et al., 1990; Albers and Sonsalla, 1995; Kuperman et al., 1997; Canini and Bourdon, 1998; He et al., 2004; Broening et al., 2005) and lethality (Davis et al., 1978; Uchima et al., 1983; Derlet et al., 1990; Bronstein and Hong, 1995). There has also been an assumption that the hyperthermia that follows methamphetamine administration is serotonin receptor-mediated (Green et al., 2003). According to these reports, we hypothesized that DAT and/or SERT mediated monoamine increase would have important roles for methamphetamine-induced hyperthermia, but the precise mechanism of the hyperthermia remains to be elucidated. In the present study, we examined hyperthermic and lethal toxic effects of methamphetamine in DAT, SERT and DAT/SERT double knockout (KO) mice to elucidate the role of these two transporters in methamphetamine-induced hyperthermia and lethality. Because methamphetamine caused paradoxical hypothermia in DAT/SERT double KO mice, we also studied the effects of selective SERT blocker (fluoxetine) and selective NET blocker (nisoxetine) on body temperature of DAT, SERT and DAT/SERT double KO mice.

Another proposed mechanism of methamphetamine-induced hyperthermia is that methamphetamine may increase hypothalamic concentrations of interleukin-1 $\beta$ , commonly known as the major endogenous pyrogen (Schobitz et al., 1994; Tringali et al., 1998; Leon, 2002). Interleukin-1 $\beta$  produces hyperthermia when introduced into the rat brain (Dascombe, et al., 1989). Methamphetamine caused a marked induction of hypothalamic interleukin-1 $\beta$  mRNA in mice (Halladay et al., 2003) and rats (Yamaguchi et al., 1991). Interleukin-1 receptor antagonists reduce the hyperthermic and lethal effects of methamphetamine in rats (Bowyer et al., 1994). Therefore, interleukin-1 $\beta$  could contribute to the hyperthermic and lethal effects of methamphetamine. To examine potential mechanisms mediated the paradoxical effects of methamphetamine on body temperature reported here in DAT/SERT double KO mice, we compared brain expression of interleukin-1 $\beta$  mRNA after methamphetamine in wild-type and DAT/SERT double KO mice.

## 2. Materials and methods

### 2.1. Subjects

Male and female DAT/SERT double KO mice weighing 15–35 g (see Bengel et al., 1998; Sora et al., 1998; Sora et al., 2001 for a full description) were used in these experiments. The effects of methamphetamine on temperature and lethality were studied in all nine potential genotypes (DAT<sup>+/+</sup> SERT<sup>+/+</sup>, DAT<sup>+/-</sup> SERT<sup>+/+</sup>, DAT<sup>-/-</sup> SERT<sup>+/+</sup>, DAT<sup>+/+</sup> SERT<sup>+/-</sup>, DAT<sup>+/-</sup> SERT<sup>+/-</sup>, DAT<sup>-/-</sup> SERT<sup>+/-</sup>, DAT<sup>+/+</sup> SERT<sup>-/-</sup>, DAT<sup>+/-</sup> SERT<sup>-/-</sup> and DAT<sup>-/-</sup> SERT<sup>-/-</sup>). All mice were bred at the Institute for Animal Experimentation in Tohoku University Graduate School of Medicine (Sendai, Japan), which met all Japanese federal government requirements for animal care and use. The genetic background of

these mice was a combination of C57BL/6J and 129Sv/J strains. For all experiments, wild-type, DAT and/or SERT KO mice pups were weaned at 28 days of age and were housed in groups of two to five, segregated by sex, in a temperature and light-controlled colony (lights on at 0800 h, lights off at 2000 h), with food and water available ad libitum. The mice were genotyped by multiplex PCR from genomic DNA extracted from tail tissue. All experiments were conducted with the approval of the Animal Ethics Committee at Tohoku University Graduate School of Medicine.

### 2.2. Body temperature measurements and lethal toxicity

All experiments were conducted at 2–3 PM in a room maintained at 20–24 °C using male and female mice of 20–30 weeks of age for each genotype. Nine genotypes of DAT/SERT KO mice received intraperitoneal injection with methamphetamine hydrochloride (45 mg/kg, 0.9% saline solution, Dainippon Pharmaceuticals, Osaka, JAPAN). Wild-type, DAT single KO, SERT single KO, and DAT/SERT double KO mice received intraperitoneal injections of fluoxetine hydrochloride (20 mg/kg, saline solution, Sigma-Aldrich Inc., St. Louis, MO, USA), or nisoxetine hydrochloride (20 mg/kg, saline solution, Sigma-Aldrich Inc., St. Louis, MO, USA). Mice were removed from their home cages, weighed, injected with the drugs, and returned to home cages in a group of 2–3 mice/cage. A digital thermometer (BAT-10; Physitemp Instruments Inc., Clifton, NJ, USA) and rectal probe for mice (RET-3, Physitemp Instruments Inc., Clifton, NJ, USA) were used to measure the body temperature of mice. The probe was inserted 2 cm into the rectum. In the present study, body temperature was measured just before (0 min) and after the injection of the drugs at 15, 30, 45 and 60 min. For lethal toxicity, 9 genotypes of DAT/SERT KO mice were removed from their home cages, weighed, injected with methamphetamine (15–150 mg/kg, saline solution), and returned to home cages in a group of 2–3 mice/cage. In preliminary tests, we found that deaths occurred within 1 h after drug injection, and most mice that were alive 1 h after the injections survived. Therefore, we measured the body temperature of mice until 1 h after methamphetamine injection and calculated lethal toxicity of methamphetamine as a percent lethality at the end of this period.

### 2.3. Determination of murine interleukin-1 $\beta$ mRNA by relative RT-PCR

Wild-type and DAT/SERT double KO mice received intraperitoneal injections of methamphetamine (saline solution, 45 mg/kg) or saline solution. One hour after the injection, mice were sacrificed by cervical dislocation. Following previously published methods (Halladay et al., 2003) the hypothalamus, nucleus caudatus, nucleus accumbens and frontal cortex were dissected on ice, and the samples were stored at –80 °C until later analysis. Total RNA was extracted using the RNeasy Mini Kit (QIAGEN, Valencia, CA, USA) for cDNA synthesis with Thermoscript RT-PCR System (Invitrogen, Carlsbad, CA, USA), to quantify relative expression of IL-1 $\beta$  mRNA with Gene Specific Relative RT-PCR Kits (Ambion, Austin, TX, USA) with QuantumRNA 18S Internal Standards (Ambion, Austin, TX, USA). For cDNA synthesis,

approximately 0.5  $\mu\text{g}$  total RNA was first denatured at 65  $^{\circ}\text{C}$  for 5 min in a 12  $\mu\text{l}$  reaction containing 2  $\mu\text{l}$  10 mM dNTP mix and 1  $\mu\text{l}$  50  $\mu\text{M}$  Oligo (dT)<sub>20</sub> and was placed on ice. After addition of 8  $\mu\text{l}$  cDNA synthesis mix containing 4  $\mu\text{l}$  5 $\times$  cDNA Synthesis Buffer, 1  $\mu\text{l}$  0.1 M dithiothreitol, 1  $\mu\text{l}$  RNaseOUT™ (40 U/ $\mu\text{l}$ ) and 1  $\mu\text{l}$  Thermoscript™ Reverse Transcriptase (15 U/ $\mu\text{l}$ ), the RNA

was reverse-transcribed at 50  $^{\circ}\text{C}$  for 60 min, denatured at 85  $^{\circ}\text{C}$  for 5 min, and finally cooled at 4  $^{\circ}\text{C}$ . After addition of 1  $\mu\text{l}$  *E. coli* RNase H (2 U/ $\mu\text{l}$ ), cDNA synthesis reaction was incubated at 37  $^{\circ}\text{C}$  for 20 min, diluted in 79  $\mu\text{l}$  Tris–EDTA solution (10 mM Tris–HCl and 1 mM EDTA, pH 8.0), and stored at –20  $^{\circ}\text{C}$  until PCR.

PCR amplification of interleukin-1 $\beta$  and 18 S cDNA was then conducted in a same tube. A 15  $\mu\text{l}$  PCR reaction was established containing 1.2  $\mu\text{l}$  2.5 mM dNTP mix, 0.075  $\mu\text{l}$  TaKaRa Ex Taq® (5 U/ $\mu\text{l}$ , TAKARA BIO Inc., Otsu, JAPAN), 1.5  $\mu\text{l}$  10 $\times$  Ex Taq Buffer (2 mM Mg<sup>2+</sup> final), 1% DMSO, 0.3  $\mu\text{l}$  Mouse IL-1 $\beta$  Relative RT-PCR primers (5  $\mu\text{M}$  mix of forward and reverse primers), 0.3  $\mu\text{l}$  mix (1:9) of 5  $\mu\text{M}$  18S PCR competitors and 5  $\mu\text{M}$  18S PCR primer pair (Ambion, Austin, TX, USA), and 3.75  $\mu\text{l}$  cDNA solution. Thermocycling involved an initial 3 min denaturation step at 94  $^{\circ}\text{C}$ , and followed by 40 cycles of 94  $^{\circ}\text{C}$  for 0.5 min, 65  $^{\circ}\text{C}$  for 0.5 min, and 72  $^{\circ}\text{C}$  for 0.5 min. PCR products were separated by 1.2 % agarose gel electrophoresis, stained with ethidium bromide and visualized by UV trans-illuminator (TDM-20, UVP Inc., Upland, CA, USA) and gel documentation system (GelPrint 2000i, Genomic Solutions Inc., Ann Arbor, MI, USA), with product size determined using a 100 bp DNA ladder (New England Biolabs, Inc, Beverly, MA, USA). ImageJ (Version 1.24, <http://rsb.info.nih.gov/ij/>), a public domain image analysis program, was used for densitometric analysis to calculate ratios for cDNA of interleukin-1 $\beta$ /cDNA of 18S rRNA.

#### 2.4. Data analysis and statistical tests

All data analysis and statistical tests were performed using SPSS statistical package (SPSS Inc., Tokyo, JAPAN), unless otherwise stated. Data from the body temperature experiments and relative RT-PCR experiments for interleukin-1 $\beta$  mRNA are presented as mean  $\pm$  S.E.M., and were submitted to analysis of variance (ANOVA). For post hoc comparisons, Dunnett's test was used for effects of methamphetamine, fluoxetine or nisoxetine on body temperature, Tukey's HSD test was used for effects of genotype on body temperature of methamphetamine-treated DAT/SERT KO mice and for effects of methamphetamine on the expression of interleukin-1 $\beta$  mRNA in the mice brain,




Fig. 1. A. Time course of body temperature of mice after intraperitoneal injection of methamphetamine (45 mg/kg). This dose of methamphetamine caused significant hyperthermia even in the mice lacking DAT. \*\*\*\* $P$ <0.001 compared to 0 min (Dunnett's test). Values represent mean  $\pm$  S.E.M.,  $n$ =10–12 mice per genotype. B. Time course of body temperature of mice after intraperitoneal injection of methamphetamine (45 mg/kg). Methamphetamine caused significant hyperthermia in DAT<sup>+/-</sup> SERT<sup>-/-</sup> and DAT<sup>-/-</sup> SERT<sup>+/-</sup> mice, but in DAT<sup>-/-</sup> SERT<sup>-/-</sup> mice, methamphetamine caused transient hypothermia followed by hyperthermia. \* $P$ <0.05; \*\*\* $P$ <0.005; and \*\*\*\* $P$ <0.001 compared to 0 min (Dunnett's test). # $P$ <0.05 compared to wild-type (Tukey's HSD test). Values represent mean  $\pm$  S.E.M.,  $n$ =14–39 mice per genotype. C. Time course of body temperature of mice after intraperitoneal injection of methamphetamine (45 mg/kg). Methamphetamine caused significant hyperthermia in DAT<sup>+/-</sup> SERT<sup>-/-</sup> and DAT<sup>-/-</sup> SERT<sup>-/-</sup> mice, but in DAT<sup>-/-</sup> SERT<sup>-/-</sup> mice, methamphetamine caused paradoxical hypothermia, revealed by significantly lower body temperature compared to 0 min as well as wild-type mice. Compared to wild-type mice, DAT<sup>+/-</sup> SERT<sup>-/-</sup> mice showed more severe hyperthermia 60 min after the injection. \*\*\*\* $P$ <0.001 compared to 0 min (Dunnett's test). #### $P$ <0.005; and ##### $P$ <0.001, compared to wild-type (Tukey's HSD test). Values represent mean  $\pm$  S.E.M.,  $n$ =7–22 mice per genotype.




Fig. 2. Time course of body temperature of mice after intraperitoneal injection of fluoxetine (20 mg/kg). Fluoxetine caused transient but significant hyperthermia in wild-type mice at 15 min after injection compared to 0 min, significant hyperthermia in DAT/SERT double KO mice from 15 to 60 min after injection compared to 0 min, and significant hypothermia in DAT single KO mice from 15 to 60 min after injection compared to 0 min, respectively. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.005$ ; and \*\*\*\* $P < 0.001$  compared to 0 min (Dunnett's test). Values represent mean  $\pm$  S.E.M.,  $n = 12$ –15 mice per genotype.

respectively. Differences in percent lethality at each dose of methamphetamine between wild-type mice and the other 8 genotypes of DAT/SERT KO mice were compared using the  $\chi^2$  test. We also calculated LD<sub>50</sub> value and its 95% confidence interval for methamphetamine in 9 genotypes of DAT/SERT KO mice by probit analysis (LC50MV5; <http://www.vector.co.jp/soft/dl/win95/edu/se125220.html>). The criterion of statistical significance was  $P < 0.05$ .

### 3. Results

#### 3.1. Body temperature by methamphetamine, fluoxetine or nisoxetine

In the 9 genotypes of DAT/SERT KO mice, there were no significant differences in basal body temperature. Following methamphetamine administration, there was a significant genotype effect on body temperature ( $F(8,157) = 16.725$ ,  $P < 0.001$ ) and significant genotype  $\times$  time interaction for changes of body temperature ( $F(32,628) = 10.792$ ,  $P < 0.001$ ). Methamphetamine significantly increased body temperature of mice with any DAT genotype and both wild-type copies of the SERT gene (wild-type, DAT<sup>+/+</sup> SERT<sup>+/+</sup>, and DAT<sup>-/-</sup> SERT<sup>+/+</sup>), and also for mice with full or single copies of the wild-type DAT gene with homozygous SERT KO (DAT<sup>+/+</sup> SERT<sup>-/-</sup> and DAT<sup>+/+</sup> SERT<sup>-/-</sup>), from 30 to 60 min after injection compared to 0 min (Fig. 1A and C). Methamphetamine also caused significant hyperthermia in SERT single heterozygous KO mice (DAT<sup>+/+</sup> SERT<sup>+/-</sup>) and DAT/SERT double heterozygous KO mice (DAT<sup>+/-</sup> SERT<sup>+/-</sup>) from 15 to 60 min after injection compared to 0 min (Fig. 1B). However, in the mice with no DAT copies and a single SERT gene copy (DAT<sup>-/-</sup> SERT<sup>+/-</sup>) methamphetamine caused significant hypothermia 15 min after injection followed by significant hyperthermia

from 45 to 60 min after injection compared to 0 min (Fig. 1B). Surprisingly, DAT/SERT double KO mice showed significant hypothermia after methamphetamine for the entire test period from 15 to 60 min after injection compared to 0 min and showed significantly lower body temperature from 30 to 60 min after injection compared to wild-type mice (Fig. 1C). The magnitude of the hyperthermic effect also varied across genotypes. Mice with no DAT copies and a single SERT gene copy (DAT<sup>-/-</sup> SERT<sup>+/-</sup>) had significantly lower body temperature after methamphetamine compared to wild-type mice (Fig. 1B) while SERT single KO mice showed significantly higher body temperature at 60 min after injection compared to wild-type (Fig. 1C).

Because methamphetamine is a potent blocker of all three monoamine transporters, methamphetamine-induced paradoxical hypothermia in DAT/SERT double KO mice might be mediated by an effect of methamphetamine on the norepinephrine transporter. Therefore, we investigated the effects of a potent blocker of SERT (fluoxetine) as well as potent blocker of NET (nisoxetine) in wild-type, DAT single KO mice, SERT single KO mice, and DAT/SERT double KO mice. Following fluoxetine administration, a significant genotype  $\times$  time interaction was observed for changes in body temperature ( $F(12,200) = 6.293$ ,  $P < 0.001$ ). Fluoxetine caused transient but significant hyperthermia in wild-type mice 15 min after injection compared to 0 min, which returned to baseline in subsequent time periods. This hyperthermic effect was prolonged in DAT/SERT double KO mice so that significant hyperthermia was observed from 15 to 60 min after injection compared to 0 min. In sharp contrast to these effects, a significant hypothermia was observed in DAT single KO mice from 15 to 60 min after injection compared to 0 min, respectively (Fig. 2). Following nisoxetine administration, there was a significant genotype effect on body temperature ( $F(3,38) = 5.690$ ,  $P < 0.005$ ) and significant genotype  $\times$  time interaction for changes in body temperature ( $F(12,152) = 6.367$ ,  $P < 0.001$ ). Nisoxetine caused significant




Fig. 3. Time course of body temperature of mice after intraperitoneal injection of nisoxetine (20 mg/kg). Nisoxetine caused significant hypothermia in DAT single KO mice from 15 to 45 min after injection compared to 0 min, and significant hyperthermia in DAT/SERT double KO mice from 15 to 60 min after injection compared to 0 min, respectively. \* $P < 0.05$ ; \*\* $P < 0.01$ ; and \*\*\*\* $P < 0.001$  compared to 0 min (Dunnett's test). Values represent mean  $\pm$  S.E.M.,  $n = 7$ –12 mice per genotype.

Table 1

Comparison of percent lethality and LD<sub>50</sub> of methamphetamine in 9 genotypes of DAT/SERT KO mice

Genotype	Percent lethality by each dose of methamphetamine (%)						LD <sub>50</sub> (mg/kg)
	Dose of methamphetamine (mg/kg)						
	15	45	75	90	110	150	
DAT <sup>+/+</sup> SERT <sup>-/-</sup>	5.0 (1/20)	24.0 (6/25)	38.1 (8/21)	57.1 (12/21)	100 (21/21)	N.A.	67.8 (55.5–81.8)
DAT <sup>+/-</sup> SERT <sup>+/+</sup>	0 (0/21)	26.7 (8/30)	31.8 (7/22)	58.3 (14/24)	84.0 (21/25)	95.5 (21/22)	73.3 (62.6–83.7)
DAT <sup>-/-</sup> SERT <sup>+/-</sup>	0 (0/9)	9.1 (1/11)	0 (0/16) <sup>b</sup>	14.3 (3/21) <sup>b</sup>	45.5 (5/11) <sup>c</sup>	100 (11/11)	112.6 (101.1–132.5)
DAT <sup>+/+</sup> SERT <sup>+/-</sup>	N.A.	6.7 (1/15)	25.0 (4/16)	83.3 (5/6)	100 (3/3)	N.A.	80.5 (69.1–103.1)
DAT <sup>+/-</sup> SERT <sup>-/-</sup>	N.A.	13.3 (6/45)	19.0 (4/21)	56.3 (9/16)	93.8 (15/16)	100 (1/1)	81.0 (71.4–95.6)
DAT <sup>-/-</sup> SERT <sup>-/-</sup>	N.A.	0 (0/18) <sup>a</sup>	11.8 (2/17)	0 (0/3)	N.A.	N.A.	N.A.
DAT <sup>+/+</sup> SERT <sup>-/-</sup>	N.A.	9.5 (2/21)	28.6 (6/21)	76.2 (16/21)	95.0 (19/20)	95.5 (21/22)	76.5 (67.9–84.5)
DAT <sup>+/-</sup> SERT <sup>-/-</sup>	N.A.	4.3 (1/23)	19.0 (4/21)	64.0 (16/25)	81.0 (17/21) <sup>a</sup>	94.7 (36/38)	86.0 (77.6–94.0)
DAT <sup>-/-</sup> SERT <sup>-/-</sup>	N.A.	0 (0/7)	0 (0/9) <sup>a</sup>	10.0 (1/10) <sup>a</sup>	20.0 (2/10) <sup>c</sup>	100 (5/5)	119.6 (108.4–141.7)

Values represent percent lethality at each dose of methamphetamine or LD<sub>50</sub>. In parentheses, number of dead mice/number of mice treated at each dose of methamphetamine is shown after percent lethality, and 95% confidence interval is shown after LD<sub>50</sub>. For DAT<sup>-/-</sup> SERT<sup>-/-</sup> mice data was not sufficient to calculate LD<sub>50</sub>. <sup>a</sup>*P*<0.05; <sup>b</sup>*P*<0.01; and <sup>c</sup>*P*<0.001 compared to wild-type mice ( $\chi^2$  test), N.A.: not applicable.

hypothermia in DAT single KO mice from 15 to 45 min after injection compared to 0 min, and significant hyperthermia in DAT/SERT double KO mice from 15 to 60 min after injection compared to 0 min, respectively (Fig. 3).

### 3.2. Lethal toxicity of methamphetamine

Table 1 shows percent lethality and LD<sub>50</sub> for methamphetamine in all 9 genotypes of DAT/SERT KO mice. In double wild-type




Fig. 4. Relative expression of interleukin-1 $\beta$  mRNA in the hypothalamus (a), nucleus caudatus (b), nucleus accumbens (c) and frontal cortex (d) of wild-type mice and DAT/SERT double KO mice after administration of saline or 45 mg/kg methamphetamine (saline solution). Methamphetamine significantly increased hypothalamic interleukin-1 $\beta$  mRNA by 5 times only in wild-type mice, compared to saline control. \*\*\*\**P*<0.001 compared to saline treated mice of same genotype (Tukey's HSD test). Values represent mean  $\pm$  S.E.M., *n*=4–7 mice per group.

mice (DAT<sup>+/+</sup> SERT<sup>+/+</sup>), the LD<sub>50</sub> for methamphetamine was estimated to be 67.8 mg/kg (95% confidence interval 55.5–81.8 mg/kg). The LD<sub>50</sub> was calculated for 7 of the other 8 genotypes, but we were unable to calculate the LD<sub>50</sub> in DAT<sup>-/-</sup> SERT<sup>+/-</sup> mice because the percent lethality was substantially reduced. Full deletion of the DAT gene, or partial or full deletion of the SERT gene, increased the LD<sub>50</sub> for methamphetamine compared to wild-type mice. DAT single KO mice and DAT/SERT double KO mice showed a significantly lower percent lethality against 75, 90, and 110 mg/kg methamphetamine compared to wild-type mice. These 2 genotypes of mice showed the first and second highest LD<sub>50</sub> values examined for methamphetamine (112.6 mg/kg for DAT single KO mice, 119.6 mg/kg for DAT/SERT double KO mice, respectively), which were 1.7–1.8 times that observed in wild-type mice. Mice with no DAT copies and a single SERT gene copy (DAT<sup>-/-</sup> SERT<sup>+/-</sup>) also showed significantly lower percent lethality against 45 mg/kg methamphetamine, suggesting that full deletion of DAT gene is protective factor against lethal toxicity of methamphetamine.

### 3.3. Effects of methamphetamine on the expression of interleukin-1 $\beta$ mRNA in the mice brain

In the hypothalamus there was a significant effect of methamphetamine on the relative expression of interleukin-1 $\beta$  mRNA ( $F(1,17)=24.666$ ,  $P<0.001$ ). There was also a significant methamphetamine  $\times$  genotype interaction ( $F(1,17)=6.154$ ,  $P<0.05$ ), reflecting genotype-dependent effects of methamphetamine on hypothalamic interleukin-1 $\beta$  mRNA. Compared to saline control, methamphetamine significantly increased hypothalamic interleukin-1 $\beta$  mRNA by 5 times in wild-type mice, but not in DAT/SERT double KO mice (Fig. 4). In the nucleus caudatus, nucleus accumbens and frontal cortex, there were no significant effects of methamphetamine on interleukin-1 $\beta$  mRNA expression, nor were there any significant methamphetamine  $\times$  genotype interactions (Fig. 4).

## 4. Discussion

These results demonstrate that methamphetamine (45 mg/kg) can exert a hyperthermic effect via DAT or via SERT in the absence of DAT. This conclusion is supported by the following observations: (1) the hyperthermic effect of methamphetamine was intact in DAT single KO mice; (2) the hyperthermic effect of methamphetamine was weakened in the mice with no DAT copies and a single SERT gene copy (DAT<sup>-/-</sup> SERT<sup>+/-</sup>), which showed transient hypothermia at 15 min after methamphetamine injection, followed by hyperthermia which was reduced compared to wild-type mice at 60 min after methamphetamine injection; and (3) no hyperthermia was observed in DAT/SERT double KO mice, which instead exhibited a paradoxical hypothermia after methamphetamine administration. Fumagalli et al. (1998) used a lower dose of methamphetamine (30 mg/kg compared to 45 mg/kg in the present study) and reported that wild-type (C57BL/129SvJ background) and DAT heterozygous mice showed hyperthermia at 1 h after single injection of methamphetamine, but DAT single KO mice did not. In accordance with these results, in initial studies we

administered 30 mg/kg methamphetamine to DAT single KO mice but observed no significant changes in body temperature from 0 to 60 min after treatment (data not shown). Subsequently we increased the dose of methamphetamine to 45 mg/kg, as presented here. This dose was the lowest enough to exert its hyperthermic effect even in the absence of DAT and caused not so high lethal toxicity. This was why we used only one dose in the hyperthermia and interleukin-1 $\beta$  experiments.

In the present study, methamphetamine (45 mg/kg) increased the body temperature (1.8 °C increment from 37.9 °C to 39.7 °C over the course of the experiment) of 20–30 week old female and male wild-type mice. There were no significant differences between female and male wild-type mice in the elevation of body temperature by methamphetamine (data not shown). Elevation of body temperature by methamphetamine was comparable to a previous study (Fumagalli et al., 1998) that used three-month-old male mice of a similar genetic background to ours (C57BL/129SvJ background) and 30 mg/kg of methamphetamine. Therefore, the differences in hyperthermic and lethal toxic effects of methamphetamine in DAT/SERT KO mice are likely to be attributed to deletion of DAT and/or SERT genes, and are not confounded with any of these other factors.

The hyperthermic effect of methamphetamine was intact in the mice with a single DAT gene copy and no SERT copies (DAT<sup>+/+</sup> SERT<sup>-/-</sup>) but reduced in mice with no DAT copies and a single SERT gene copy (DAT<sup>-/-</sup> SERT<sup>+/-</sup>), suggesting that half-normal expression of DAT (without SERT expression) was enough for methamphetamine to raise body temperature of mice, but half-normal expression of SERT (without DAT) was not. Therefore, the contribution of DAT to the hyperthermic effect of methamphetamine seems to be much larger than the contribution of SERT, although SERT possibly compensates to maintain the hyperthermic effect of methamphetamine in the absence of DAT. Intriguingly, the current results for hyperthermia produced by methamphetamine in DAT/SERT KO mice appear similar to our previous studies of cocaine-induced place preference (Sora et al., 2001; Murphy et al., 2003) as well as our recent microdialysis data on cocaine-induced extracellular dopamine concentrations in caudate putamen (Shen et al., 2004) in these mice. Both the mice with no DAT copies and a single SERT gene copy and DAT/SERT double KO mice failed to exhibit rewarding effects of cocaine (Sora et al., 2001) or increases in extracellular dopamine concentrations in the caudate putamen after cocaine (Shen et al., 2004). Although several mechanisms might underlie these findings, these data are consistent with the hypothesis that the absence of cognate DAT might allow dopamine to be accumulated by SERT (and/or NET), allowing cocaine to act at these targets to affect extracellular DA levels (Shen et al., 2004).

Methamphetamine caused unexpected and paradoxical hypothermia in DAT/SERT double KO mice. Since there has not been any report that DAT and/or SERT gene deletion could affect drug metabolism, it seems to be unlikely that this paradoxical hypothermia in DAT/SERT double KO mice was due to differences in the metabolism of methamphetamine. One possible explanation for this could be that methamphetamine could act on NET in DAT/SERT double KO mice to cause hypothermia, but this hypothesis was not supported by other data, as nisoxetine



caused significant hyperthermia in DAT/SERT double KO mice. Nisoxetine did not affect the body temperature in wild-type mice, so nisoxetine-induced hyperthermia in DAT/SERT double KO mice must have resulted from interactions between the effect of nisoxetine and neuroadaptations to chronic DAT and/or SERT loss in DAT/SERT double KO mice (Sora et al., 2001). Fluoxetine, the selective SERT blocker, has a weak binding potency for NET (Owens et al., 2001; Orjales et al., 2003), and also caused hyperthermia in DAT/SERT double KO mice supporting the idea that NET blockade in DAT/SERT double KO mice could lead to hyperthermia. In any case the current data showed that the norepinephrine system is not responsible for methamphetamine-induced paradoxical hypothermia in DAT/SERT double KO mice.

In contrast to the observations in combined DAT/SERT double KO mice both fluoxetine and nisoxetine caused hyperthermia in DAT single KO mice but did not affect the body temperature of SERT single KO mice. As in DAT/SERT double KO mice, DAT single KO mice and SERT single KO mice show neuroadaptive changes in both postsynaptic receptors, and presynaptic neurotransmitter levels (Sora et al., 2001). Our results reflect complex interactions between actions of fluoxetine or nisoxetine and neurochemical backgrounds of DAT KO, SERT KO, and DAT/SERT double KO mice. We have previously found evidence for adaptations that affect responses to selective monoamine transporter blockers in DAT KO mice (Hall et al., 2002).

Previous animal studies suggest that dopamine receptor activation is crucial for amphetamine- or methamphetamine-induced lethality (Davis et al., 1978; Uchima et al., 1983; Derlet et al., 1990; Bronstein and Hong, 1995). These results suggest that lethal effects of amphetamines are closely related to their indirect agonistic effects on the dopaminergic terminals/neurons via DAT, which displaces both vesicular and intracellular dopamine and facilitates release of dopamine into the extraneuronal space by synaptic transport (Seiden et al., 1993). In our experiments, full deletion of DAT and full or partial deletion of SERT increased methamphetamine LD<sub>50</sub> compared to wild-type mice, suggesting that both DAT and SERT have a role in the lethal toxicity of methamphetamine. Especially in DAT single KO mice and DAT/SERT double KO mice, DAT deletion strikingly increased the LD<sub>50</sub> for methamphetamine to 1.7–1.8 times that observed in wild-type mice. Moreover, mice with DAT deletion (DAT single KO mice, DAT<sup>-/-</sup> SERT<sup>+/-</sup>, and DAT/SERT double KO mice) all showed significantly lower percent lethality against methamphetamine (45 mg/kg in DAT<sup>-/-</sup> SERT<sup>+/-</sup>, 75, 90, and 110 mg/kg in DAT single KO mice and DAT/SERT double KO mice) compared to wild-type mice, indicating a major role of DAT in the lethal toxicity produced by methamphetamine. On the other hand, addition of SERT deletion slightly increased LD<sub>50</sub>. However, these small but consistent differences produced by SERT deletion were not statistically significant, so the lethal toxic effect of methamphetamine is mainly dependent on DAT.

In comparing the results of the temperature and lethality studies across the DAT/SERT genotypes, it is obvious that hyperthermia is not a prerequisite for methamphetamine-induced lethality. Previous clinical and animal studies suggest that hyperthermia is the primary cause of death by methamphetamine (Bowyer et al., 1994; Davidson et al., 2001; Namiki et al., 2005). But in our experiments,

there was a dissociation between hyperthermic and lethal toxic effects of methamphetamine in DAT single KO mice and DAT/SERT double KO mice. The former mice showed hyperthermia and the latter showed hypothermia by methamphetamine, respectively, but both showed markedly elevated LD<sub>50</sub> values for methamphetamine compared to wild-type mice. So, contrary to the previous conceptions of the causes of methamphetamine-induced toxicity, methamphetamine-induced hyperthermia does not appear to be the mediator of lethal toxicity produced by methamphetamine.

Yamaguchi et al. (1991) reported that 2–15 mg/kg methamphetamine caused a marked induction of interleukin-1 $\beta$  mRNA exclusively in the hypothalamus of rats which peaked at 1 h after administration. Halladay et al. (2003) reported that 8 mg/kg methamphetamine increased hypothalamic expression of interleukin-1 $\beta$  mRNA in BALB/c mice at 2 h after administration. Bowyer et al. (1994) reported that interleukin-1 receptor antagonist reduced maximal body temperature by methamphetamine in rats. We also observed that methamphetamine significantly increased hypothalamic interleukin-1 $\beta$  mRNA in wild-type mice, but not in DAT/SERT double KO mice, that fail to exhibit methamphetamine-induced hyperthermia. Since interleukin-1 $\beta$  is known to be the major endogenous pyrogen (Dascombe et al., 1989; Schobitz et al., 1994; Tringali et al., 1998; Leon, 2002), our finding can provide a partial explanation of the mechanism of methamphetamine-induced paradoxical hypothermia in DAT/SERT double KO mice: methamphetamine did not increase hypothalamic interleukin-1 $\beta$  mRNA in the mice, and thus could not raise their body temperature. But as to the methamphetamine-induced decrease in body temperature observed in DAT/SERT double KO mice, the precise mechanism remains unknown. We also examined methamphetamine-induced interleukin-1 $\beta$  mRNA in the nucleus accumbens, nucleus caudatus and frontal cortex, which were not involved in temperature regulation (Leon, 2002) since methamphetamine significantly increased TNF- $\alpha$  mRNA, another endogenous pyrogen, in the nucleus accumbens and caudatus but not in the frontal cortex of mice (Nakajima et al., 2004). But we did not find any significant changes in these brain regions.

In conclusion, these studies have demonstrated that the hyperthermic effect of methamphetamine is dependent on DAT, and in the absence of DAT, on SERT. Furthermore, combined deletion of both the DAT and SERT genes in mice resulted in a paradoxical hypothermia produced by methamphetamine. Although the noradrenergic system does not appear to be responsible for methamphetamine-induced paradoxical hypothermia in DAT/SERT double KO mice, a partial explanation of this mechanism is that methamphetamine failed to increase hypothalamic interleukin-1 $\beta$  mRNA in DAT/SERT double KO mice. Although DAT and SERT were shown here to be involved in both the effects of methamphetamine on temperature as well as methamphetamine lethal toxicity, the mechanisms are nonetheless different; DAT single KO mice exhibited hyperthermia but greatly reduced methamphetamine lethality, and the lethality was no different from DAT/SERT double KO mice that had hypothermic responses to methamphetamine. Thus, although the lethal toxic effect of methamphetamine is mainly dependent on

DAT, with some contribution from SERT, hyperthermia is not prerequisite for methamphetamine-induced lethality.

### Acknowledgements

We thank Ms. Kayo Ohmi and Ms. Maki Naka for their assistance. This study was supported in part by Grant-in-Aid for Health and Labor Science Research (Research on Pharmaceutical and Medical Safety) from the Ministry of Health, Labor and Welfare of Japan; by Grants-in-Aid for Scientific Research (B), Scientific Research on Priority Areas — System study on higher-order brain functions and Research on Pathomechanisms of Brain Disorders, Core Research for Evolutional Science and Technology (CREST), from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 17390315, 17022007, 18023007); and by the Mitsubishi Pharma Research Foundation. This study was also supported in part by intramural funding from the National Institute on Drug Abuse, NIH/DHHS (USA).

### References

- Albers, D.S., Sonsalla, P.K., 1995. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. *J. Pharmacol. Exp. Ther.* 275, 1104–1114.
- Ali, S.F., Newport, G.D., Holson, R.R., Slikker Jr., W., Bowyer, J.F., 1994. Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. *Brain Res.* 658, 33–38.
- Bengel, D., Murphy, D.L., Andrews, A.M., Wichems, C.H., Felner, D., Heils, A., Mossner, R., Westphal, H., Lesch, K.P., 1998. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine (“Ecstasy”) in serotonin transporter-deficient mice. *Mol. Pharmacol.* 53, 649–655.
- Bowyer, J.F., Davies, D.L., Schmued, L., Broening, H.W., Newport, G.D., Slikker Jr., W., Holson, R.R., 1994. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. *J. Pharmacol. Exp. Ther.* 268, 1571–1580.
- Broening, H.W., Morford, L.L., Vorhees, C.V., 2005. Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions. *Synapse* 56, 84–93.
- Bronstein, D.M., Hong, J.S., 1995. Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality. *J. Pharmacol. Exp. Ther.* 274, 943–950.
- Canini, F., Bourdon, L., 1998. Dopamine involvement in thermoregulatory responses to heat in rats. *Neurosci. Lett.* 241, 91–94.
- Chan, T.C., Evans, S.D., Clark, R.F., 1997. Drug-induced hyperthermia. *Crit. Care Clin.* 13, 785–808.
- Dascombe, M.J., Rothwell, N.J., Sagay, B.O., Stock, M.J., 1989. Pyrogenic and thermogenic effects of interleukin 1 beta in the rat. *Am. J. Physiol.* 256, E7–E11.
- Davidson, C., Gow, A.J., Lec, T.H., Ellinwood, E.H., 2001. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. *Brain Res. Brain Res. Rev.* 36, 1–22.
- Davis, W.M., Hatoum, H.T., Waters, I.W., 1978. Interactions of catecholaminergic receptor blockers with lethal doses of amphetamine or substituted amphetamines in mice. *Res. Commun. Chem. Pathol. Pharmacol.* 21, 27–36.
- Derlet, R.W., Albertson, T.E., Rice, P., 1990. Antagonism of cocaine, amphetamine, and methamphetamine toxicity. *Pharmacol. Biochem. Behav.* 36, 745–749.
- Fumagalli, F., Gainetdinov, R.R., Valenzano, K.J., Caron, M.G., 1998. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. *J. Neurosci.* 18, 4861–4869.
- Funahashi, M., Kohda, H., Hori, O., Hayashida, H., Kimura, H., 1990. Potentiating effect of morphine upon D-methamphetamine-induced hyperthermia in mice. Effects of naloxone and haloperidol. *Pharmacol. Biochem. Behav.* 36, 345–350.
- Green, A.R., Mehan, A.O., Elliott, J.M., O’Shea, E., Colado, M.I., 2003. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). *Pharmacol. Rev.* 55, 463–508.
- Hall, F.S., Li, X.F., Sora, I., Xu, F., Caron, M., Lesch, K.P., Murphy, D.L., Uhl, G.R., 2002. Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. *Neuroscience* 115, 153–161.
- Halladay, A.K., Kusnecov, A., Michna, L., Kita, T., Hara, C., Wagner, G.C., 2003. Relationship between methamphetamine-induced dopamine release, hyperthermia, self-injurious behaviour and long term dopamine depletion in BALB/c and C57BL/6 mice. *Pharmacol. Toxicol.* 93, 33–41.
- Hanson, G.R., Rau, K.S., Fleckenstein, A.E., 2004. The methamphetamine experience: a NIDA partnership. *Neuropharmacology* 47 (Suppl 1), 92–100.
- He, J., Xu, H., Yang, Y., Zhang, X., Li, X.M., 2004. Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of Bcl-2 decrease in rats. *Brain Res.* 1018, 186–192.
- Imam, S.Z., Ali, S.F., 2001. Aging increases the susceptibility to methamphetamine-induced dopaminergic neurotoxicity in rats: correlation with peroxynitrite production and hyperthermia. *J. Neurochem.* 78, 952–959.
- Kita, T., Wagner, G.C., Nakashima, T., 2003. Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. *J. Pharmacol. Sci.* 92, 178–195.
- Kuperman, D.I., Freyaldenhoven, T.E., Schmued, L.C., Ali, S.F., 1997. Methamphetamine-induced hyperthermia in mice: examination of dopamine depletion and heat-shock protein induction. *Brain Res.* 771, 221–227.
- Leon, L.R., 2002. Invited review: cytokine regulation of fever: studies using gene knockout mice. *J. Appl. Physiol.* 92, 2648–2655.
- Miller, D.B., O’Callaghan, J.P., 2003. Elevated environmental temperature and methamphetamine neurotoxicity. *Environ. Res.* 92, 48–53.
- Murphy, D.L., Uhl, G.R., Holmes, A., Ren-Patterson, R., Hall, F.S., Sora, I., Detera-Wadleigh, S., Lesch, K.P., 2003. Experimental gene interaction studies with SERT mutant mice as models for human polygenic and epistatic traits and disorders. *Genes Brain Behav.* 2, 350–364.
- Nakajima, A., Yamada, K., Nagai, T., Uchiyama, T., Miyamoto, Y., Mamiya, T., He, J., Nitta, A., Mizuno, M., Tran, M.H., Seto, A., Yoshimura, M., Kitaichi, K., Hasegawa, T., Saito, K., Yamada, Y., Scishima, M., Sekikawa, K., Kim, H.C., Nabeshima, T., 2004. Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity. *J. Neurosci.* 24, 2212–2225.
- Namiki, M., Mori, T., Sawaguchi, T., Ito, S., Suzuki, T., 2005. Underlying mechanism of combined effect of methamphetamine and morphine on lethality in mice and therapeutic potential of cooling. *J. Pharmacol. Sci.* 99, 168–176.
- Orjales, A., Mosquera, R., Toledo, A., Pumar, M.C., Garcia, N., Cortizo, L., Labeaga, L., Innerarity, A., 2003. Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters. *J. Med. Chem.* 46, 5512–5532.
- Owens, M.J., Knight, D.L., Nemcroff, C.B., 2001. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. *Biol. Psychiatry* 50, 345–350.
- Sato, M., Numachi, Y., Hamamura, T., 1992. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. *Schizophr. Bull.* 18, 115–122.
- Schobitz, B., De Kloet, E.R., Holsboer, F., 1994. Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain. *Prog. Neurobiol.* 44, 397–432.
- Seiden, L.S., Sabol, K.E., Ricaurte, G.A., 1993. Amphetamine: effects on catecholamine systems and behavior. *Annu. Rev. Pharmacol. Toxicol.* 33, 639–677.
- Shen, H.W., Hagino, Y., Kobayashi, H., Shinohara-Tanaka, K., Ikeda, K., Yamamoto, H., Yamamoto, T., Lesch, K.P., Murphy, D.L., Hall, F.S., Uhl, G.R., Sora, I., 2004. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. *Neuropsychopharmacology* 29, 1790–1799.
- Sora, I., Hall, F.S., Andrews, A.M., Itokawa, M., Li, X.F., Wei, H.B., Wichems, C., Lesch, K.P., Murphy, D.L., Uhl, G.R., 2001. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. *Proc. Natl. Acad. Sci. U. S. A.* 98, 5300–5305.

- Sora, I., Wichems, C., Takahashi, N., Li, X.F., Zeng, Z., Revay, R., Lesch, K.P., Murphy, D.L., Uhl, G.R., 1998. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. *Proc. Natl. Acad. Sci. U. S. A.* 95, 7699–7704.
- Tringali, G., Dello Russo, C., Preziosi, P., Navarra, P., 1998. Hypothalamic interleukin-1 in physiology and pathology. *Toxicol. Lett.* 102–103, 295–299.
- Uchima, E., Ogura, Y., Hiraga, Y., Shikata, I., 1983. Relationship between methamphetamine toxicity and catecholamine levels in heart and brain of mice. *Nippon Hoigaku Zasshi* 37, 198–208.
- Wagner, G.C., Tekirian, T.L., Cheo, C.T., 1993. Sexual differences in sensitivity to methamphetamine toxicity. *J. Neural Transm. Gen. Sect.* 93, 67–70.
- Yamaguchi, T., Kuraishi, Y., Minami, M., Nakai, S., Hirai, Y., Satoh, M., 1991. Methamphetamine-induced expression of interleukin-1 beta mRNA in the rat hypothalamus. *Neurosci. Lett.* 128, 90–92.

# Genome-Wide Association for Methamphetamine Dependence

## Convergent Results From 2 Samples

George R. Uhl, MD, PhD; Tomas Drgon, PhD; Qing-Rong Liu, PhD; Catherine Johnson, MSc; Donna Walther, MSc; Tokutaro Komiyama, MD; Mutsuo Harano, MD; Yoshimoto Sekine, MD, PhD; Toshiya Inada, MD; Norio Ozaki, MD, PhD; Masaomi Iyo, MD, PhD; Nakao Iwata, MD, PhD; Mitsuhiro Yamada, MD; Ichiro Sora, MD, PhD; Chih-Ken Chen, MD, PhD; Hsing-Cheng Liu, MD, PhD; Hiroshi Ujike; Shih-Ku Lin, MD

**Context:** We can improve understanding of human methamphetamine dependence, and possibly our abilities to prevent and treat this devastating disorder, by identifying genes whose allelic variants predispose to methamphetamine dependence.

**Objective:** To find "methamphetamine dependence" genes identified by each of 2 genome-wide association (GWA) studies of independent samples of methamphetamine-dependent individuals and matched controls.

**Design:** Replicated GWA results in each of 2 case-control studies.

**Setting:** Japan and Taiwan.

**Participants:** Individuals with methamphetamine dependence and matched control subjects free from psychiatric, substance abuse, or substance dependence diagnoses (N=580).

**Main Outcome Measures:** "Methamphetamine dependence" genes that were reproducibly identified by clusters of nominally positive single-nucleotide polymorphisms (SNPs) in both samples in ways that were unlikely to represent chance observations, based on Monte Carlo simulations that corrected for multiple comparisons, and

subsets of "methamphetamine dependence" genes that were also identified by GWA studies of dependence on other addictive substances, success in quitting smoking, and memory.

**Results:** Genes identified by clustered nominally positive SNPs from both samples were unlikely to represent chance observations (Monte Carlo  $P < .00001$ ). Variants in these "methamphetamine dependence" genes are likely to alter cell adhesion, enzymatic functions, transcription, cell structure, and DNA, RNA, and/or protein handling or modification. Cell adhesion genes *CSMD1* and *CDH13* displayed the largest numbers of clustered nominally positive SNPs. "Methamphetamine dependence" genes overlapped, to extents much greater than chance, with genes identified in GWA studies of dependence on other addictive substances, success in quitting smoking, and memory (Monte Carlo  $P$  range  $< .04$  to  $< .00001$ ).

**Conclusion:** These data support polygenic contributions to methamphetamine dependence from genes that include those whose variants contribute to dependence on several addictive substances, success in quitting smoking, and mnemonic processes.

*Arch Gen Psychiatry.* 2008;65(3):345-355

**M**ETHAMPHETAMINE abuse is a growing problem in many regions of the United States and a long-standing concern in Taiwan and Japan. Elucidating which genetic variants enhance individuals' vulnerability should increase our understanding of methamphetamine dependence.

Recent reviews suggest that addictive substance dependence is likely to display a polygenic genetic architecture.<sup>1-3</sup> Psychostimulant dependence displays strong familial and genetic influences in family and twin studies.<sup>4-18</sup> Individual differences in vulnerability to methamphetamine are thus likely to display substan-

tial genetic determinants. Since much of the genetic vulnerability to stimulant abuse overlaps with the genetics of vulnerability to other classes of addictive substances, it is likely that methamphetamine dependence displays such genetic overlaps as well.<sup>13-16,19</sup> However, there is no evidence that any single gene's variants mediate a large portion of vulnerability to psychostimulant dependence.

Identifying the genes that harbor allelic variants that contribute to human individual differences in vulnerabilities to methamphetamine dependence will help us to understand processes that underlie human addictions. We may improve understanding of the relative contributions of variants in the brain systems that underlie

Author Affiliations are listed at the end of this article.

reward vs mnemonic components of addictions, for example.<sup>20</sup> Increasing our ability to determine which constellation of genetic and environmental factors plays a role in the methamphetamine dependence of each affected individual should improve "personalized" targeting of treatment and prevention efforts to those most likely to benefit from them.

Genome-wide association (GWA) can help to elucidate chromosomal regions and genes that contain allelic variants that predispose to substance abuse. This approach does not require family member participation. It gains power as densities of genomic markers increase.<sup>21-24</sup> Association identifies smaller chromosomal regions than linkage-based approaches. Genome-wide association fosters pooling strategies that preserve confidentiality and reduce costs, including those that we have previously validated.<sup>25-28</sup> This approach provides ample genomic controls that can minimize the chances of unintended ethnic mismatches between disease and control samples (eg, stratification). The large numbers of assessments that are key components of GWA do mandate careful use of statistical approaches that correct for multiple comparisons and studies in multiple independent samples, such as those that we now report.

We thus now describe GWA in 2 samples of methamphetamine-dependent and control individuals. These studies test the a priori hypothesis that marker allele frequency differences between methamphetamine-dependent and control individuals will help us to identify genes whose alleles predispose to development of dependence on methamphetamine. Sample 1 contrasts (1) Han Chinese methamphetamine-dependent individuals from the Taipei region of Taiwan with (2) age- and sex-matched Han Chinese Taiwanese control individuals free from any histories of abuse or dependence on any legal or illegal addictive substance. Sample 2 contrasts (1) Japanese methamphetamine-dependent individuals with (2) age- and sex-matched Japanese control individuals free from any histories of abuse or dependence on any legal or illegal addictive substance. We used standard statistical approaches to document the power that these samples provided to identify genetic influences of different magnitudes. We identified striking convergence of the data from sample 1 and sample 2, in ways that are never attained by chance in many Monte Carlo simulation trials. We discuss the convergence that these data provide with recently reported GWA studies of related phenotypes that include polysubstance abuse, nicotine dependence, alcohol dependence, success in quitting smoking, and individual differences in memory. To our knowledge, these results provide the first replicated GWA study that identifies "methamphetamine dependence" genes.

## METHODS

### RESEARCH VOLUNTEERS

#### Sample 1

Subjects recruited in Taipei provided informed consent for genetic studies under protocols approved by ethics committees at the respective institutions; 30% were female and the mean

(SD) age was 32.5 (10) years. One hundred forty individuals were diagnosed independently by each of 2 psychiatrists based on interviews, review of records, and Chinese versions of the Diagnostic Interview for Genetic Studies<sup>29</sup> and the Family Interview for Genetic Studies<sup>30</sup> using DSM-IV criteria.<sup>31</sup> These individuals were of ethnic Han Chinese origin and older than 17 years, reported methamphetamine use more than 20 times per year (unless they described well-documented methamphetamine psychosis), and denied histories of psychosis either prior to methamphetamine use or in relation to other psychedelic drugs. Most reported use of at least 1 other addictive substance. Two hundred forty Han Chinese controls, who were matched for sex and age, were older than 17 years, and denied either illegal drug use or psychotic symptoms to psychiatric interviewers, were recruited in Taipei from hospital and pharmacy staffs, blood donation centers, and an electric company.

#### Sample 2

Subjects who were born and resided in the northern Kyushu, Setouchi, Chiba, Tokai, or Kanto regions of Japan provided informed consent for genetic studies under protocols approved by ethics committees at the respective institutions. Twenty-one percent of subjects were female and the mean (SD) age was 39.9 (13) years. One hundred methamphetamine-dependent subjects were inpatients or outpatients of psychiatric hospitals in these regions that participate in the Japanese Genetics Initiative for Drug Abuse<sup>32-45</sup> and met *International Statistical Classification of Diseases, 10th Revision, Diagnostic Criteria for Research*<sup>46</sup> criteria F15.2 and F15.5 for methamphetamine dependence in independent diagnoses made by each of 2 trained psychiatrists based on interviews and review of records. Ninety-one percent revealed histories of methamphetamine psychosis, 89% used methamphetamine intravenously, 62% also abused organic solvents, and most abused at least 1 other substance. Subjects who displayed clinical diagnoses of schizophrenia, other psychotic disorders, or organic mental syndromes were excluded. Controls were 100 age-, sex-, and geographically matched staff recruited at the same institutions, who denied use of any illegal substance, abuse or dependence on any legal substance, any psychotic psychiatric illness, or any family history of substance dependence or psychotic psychiatric illness during interviews with trained psychiatrists.

### DNA PREPARATION AND ASSESSMENT OF ALLELE FREQUENCIES

Genomic DNA was prepared from blood,<sup>28,32,47,48</sup> quantitated,<sup>28,32</sup> and combined into pools representing 20 individuals of the same ethnicity and phenotype. Relative allele frequencies were assessed using Affymetrix (Santa Clara, California) microarrays.

Hybridization probes were prepared from the genomic DNA pools (as described in the Affymetrix GeneChip Mapping Assay manual), with precautions to avoid contamination that included dedicated preparation rooms and hoods. Briefly, 50 ng of pooled genomic DNA was digested by *Xba*I or *Hind*III (100K) or by *Sty*I or *Nsp*I (500K), ligated to appropriate adaptors, and amplified using a GeneAmp PCR System 9700 (Applied Biosystems, Foster City, California) with a 3-minute 94°C hot start; 30 cycles of 30 seconds at 94°C, 45 seconds at 60°C, and 60 seconds at 68°C (100K) or 15 seconds at 68°C (500K); and a final 7-minute 68°C extension. Polymerase chain reaction (PCR) products were purified (MinElute 96 UF kits; Qiagen, Valencia, California) and quantitated. Forty micrograms of PCR product were digested for 35 minutes at 37°C with 0.04-unit/μL deoxyribonuclease I to produce 30- to 100-base pair fragments, which were end-labeled using terminal deoxynucleotidyl trans-

ferase and biotinylated dideoxynucleotides and hybridized to the appropriate 100K (*Xba*I or *Hind*III arrays) or 500K (*Sty*I or *Nsp*I arrays) array (early-access Centurion and commercial Mendel array sets; Affymetrix). Arrays were stained and washed as described in the Affymetrix GeneChip Mapping Assay manual using immunopure streptavidin (Pierce, Milwaukee, Wisconsin), biotinylated antistreptavidin antibody (Vector Labs, Burlingame, California), and R-phycoerythrin streptavidin (Molecular Probes, Eugene, Oregon). Arrays were scanned and fluorescence intensities were quantitated using an Affymetrix array scanner, as described previously.<sup>28</sup> Estimates for "genomic coverage" for these marker densities were almost 0.8 (sample 1) and almost 0.9 (sample 2).<sup>49</sup>

Chromosomal positions for each single-nucleotide polymorphism (SNP) were sought using NCBI (build 36.1; National Center for Biotechnology Information, Bethesda, Maryland) and NetAffyx (Affymetrix) data. Allele frequencies for each SNP in each DNA pool were assessed based on hybridization intensity signals from 4 arrays, allowing assessment of hybridization to the 20 (100K arrays) or 12 (500K arrays) "perfect match" cells on each array that were complementary to the PCR products from alleles "A" and "B" for each diallelic SNP on sense and antisense strands. We eliminated (1) SNPs with minor allele frequencies less than 0.02 determined using Affymetrix data; (2) SNPs on sex chromosomes; and (3) SNPs whose chromosomal positions could not be adequately determined. We thus analyzed data from the remaining 371 820 and 466 883 SNPs (for sample 1 and sample 2, respectively) in detail. Each array was analyzed, as described previously,<sup>28</sup> subtracting background values, normalizing to the highest values noted on the array, averaging the hybridization intensities from the array cells that corresponded to the perfect match "A" and "B" cells, calculating "A/B ratios" by dividing average normalized A values by average normalized B values, performing arctangent transformations to aid combination of data from arrays hybridized and scanned on different days, and determining the average arctan value for each SNP from the 4 replicate arrays. This approach is thus based on hybridization intensity data from Affymetrix scanners rather than relative allele score (RAS) or *k* corrections derived from RAS scores.<sup>50,51</sup>

The analyses presented in this work use standard methods for correcting hybridization values for each perfect match feature based on chip-to-chip differences in background fluorescence and in total fluorescence intensity. These approaches have generated good, approximately 0.95, correlations between individually genotyped and pooled-genotype values in extensive validation experiments.<sup>32,52</sup> Other approaches to analysis of pooling-based GWA studies have focused on the RAS measurements that derive from Affymetrix software to generate *k* correction scores for each SNP that attempt to correct for probe  $\times$  probe variation (ie, that induced by, or consistent with, differential hybridization effects).<sup>50,51</sup> In studies that have used these corrections, correlations between individually and pooled genotyped SNP allelic frequencies can equal or exceed those that we have observed in validation experiments.<sup>53,54</sup> However, RAS scores have been used less and less as the genotype-calling algorithms for successive generations of Affymetrix arrays have improved their accuracy. Initial RAS scores are based in part on data from mismatch cells, which have again been eliminated from successive generations of Affymetrix arrays because of their inconsistent effects on accuracy. The *k* corrections based on RAS scores that are generated in different laboratories produce differing results.<sup>55</sup> Further, we have found that substantial numbers of the array features that provide information for the RAS scores are saturated under conditions used to conduct individual genotyping (Q-R.L., D.W., and G.R.U., unpublished data, 2005), leading us to use smaller amounts of input DNA and hybridization probes for the pooled assays reported herein. The *k* corrections may prove to

be useful for experiments in which saturation is controlled carefully and where data from heterozygote control individuals are generated in the same experiments and in the same laboratories as the pooling data. However, in the present analysis, this adds to the variation that we already parse as quantified by replicate pools (ie, biological haplotype replication), applications of different chips to the same pool (ie, chip-oriented technical replication), and different samples altogether (ie, overall association replication).

## ANALYSES

We compared data for all the pools from methamphetamine-dependent individuals with all of the pools from control individuals separately for sample 1 and sample 2, as previously described.<sup>28</sup> A *t* statistic for the differences between abusers and controls was generated, as described previously,<sup>28</sup> for each SNP for each sample. For each sample, we focused on "nominally positive" SNPs that displayed *t* statistics with  $P < .05$  for abuser-control differences. We first sought evidence for clustering of the nominally positive SNPs from each sample. We focused on chromosomal regions in which at least 3 of these nominally positive SNPs, assessed by at least 2 different array types, lay within 25 kilobases (kb) of each other. We term these clustered nominally positive SNPs *clustered positive SNPs* and focus our analyses on regions in which they lie. The degree of clustering within each single sample provides a technical control (eg, assurance that there are haplotypes that occur at different frequencies in dependent vs control samples) that could result from stochastic differences in haplotypes as well as differences related to the methamphetamine-dependence phenotype.

To seek the SNPs within the strongest positive support from both data sets, we sought convergence between data from sample 1 and sample 2 (**Table**).<sup>56</sup> Analyses focused on genes identified by clustered positive results from both samples, rather than on individual SNPs whose informativeness might differ between samples 1 and 2. Clustering of positive results in the same gene in each of 2 independent samples is unlikely to represent purely stochastic effects for most genes and is thus likely to reflect differences related to dependence on methamphetamine (and/or to dependence on addictive substances in general).

Monte Carlo simulation trials assessed the significance of the results in ways that correct for the number of repeated comparisons made herein, as described previously.<sup>28</sup> These empirical statistical approaches do not require assumptions about the underlying distribution of the data sets, as do statistical approaches such as analysis of variance, and allow correction for the hundreds of thousands of repeated comparisons in ways that would provide difficulties for repeated analyses of variance. For each trial, a randomly selected set of SNPs from the current data set was assessed to see if it provided results equal to or greater than the results that we actually observed (eg, to see how frequently randomly selected sets of 15 565 SNPs from sample 1 and 25 538 SNPs from sample 2 contained nominally positive SNPs that lie clustered within 25 kb of each other on the chromosomes, see "Results" section). The number of trials for which the randomly selected SNPs displayed the same features of observed results was then tallied to generate an empirical *P* value. These simulations thus corrected for the number of repeated comparisons made in these analyses, an important consideration in evaluating this large association genome scanning data set. We used a similar approach to assess the likelihood that the convergences between the current data and data obtained from other samples might occur by chance.

To seek possible generalization of these results, we sought locations where the clustered positive data from both sample 1 and sample 2 lie at chromosomal positions near clustered positive results from studies that compared allelic frequencies in

**Table. Selected "Methamphetamine Dependence" Genes Identified by Clustered Positive Results From Both Sample 1 and Sample 2<sup>a</sup>**

Gene	Class	Description	SNPs <sup>b</sup>	P Value <sup>c</sup>
SGCZ	CAM	Sarcoglycan, zeta	3, 20	<.00001
DAF/CD55	ENZ	Decay-accelerating factor for complement system	1, 4	<.00001
ACSL6	ENZ	Acyl-CoA synthetase long-chain family member 6	9, 5	<.00001
FKBP15	ENZ	FKBP15	4, 4	<.00001
PDE6C	ENZ	cGMP phosphodiesterase 6C $\alpha'$	4, 7	<.00001
POU5F1	TF	POU-domain 5 transcription factor 1	1, 5	<.00001
SH3MD4	PROT	SH3 multiple domains 4	9, 7	<.00001
RALY	RNA	Autoantigenic RNA binding protein	5, 3	<.00001
PRKG1	ENZ	cGMP-dependent protein kinase I	14, 5	.00001
LARGE	ENZ	Like-glycosyltransferase	11, 3	.00001
PCOLCE2	STR	Procollagen C endopeptidase enhancer 2	3, 2	.00001
MOSC2	ENZ	MOCO sulphurase C-terminal domain containing 2	4, 5	.00002
ZNF423	TF	Zinc finger protein 423	5, 4	.00002
MAP2K5	ENZ	Mitogen-activated protein kinase kinase 5	5, 3	.00003
USP48	PROT	Ubiquitin-specific peptidase 48	3, 2	.00003
SMYD3	TF	SET MYND domain containing 3	7, 5	.00007
CCHCR1	REC	Coiled-coil $\alpha$ -helical rod protein 1	2, 4	.00009
LRRN6C	CAM	Leucine-rich repeat neuronal 6C	4, 13	.00010
CENPC2	STR	Centromere protein C2	2, 3	.00012
RAPGEF5	REC	Rap guanine nucleotide exchange factor 5	4, 1	.00016
SERPINA5	ENZ	Serpin peptidase inhibitor A 5	4, 1	.00018
PRDM2	TF	PR domain containing 2 with ZNF domain	6, 3	.00022
ASTN2	CAM	Astrotactin 2	12, 3	.00037
TM7SF4	PROT	Transmembrane 7 superfamily member 4	2, 3	.00037
TRPM3	CHAN	Transient receptor potential cation channel, subfamily M, member 3	4, 10	.00039
RGS17	ENZ	Regulator of G-protein signaling 17	4, 3	.00047
COL28A1	STR	Collagen, type XXVIII, alpha 1	4, 3	.00047
MOSC1	ENZ	MOCO sulphurase C-terminal domain containing 1	5, 1	.00048
PDE4B	ENZ	Phosphodiesterase 4B	8, 4	.00049
AOAH	ENZ	Acyloxyacyl hydrolase	3, 4	.00049
PDE4D	ENZ	Phosphodiesterase 4D	6, 6	.00057
ZNF659	TF	Zinc finger protein 659	6, 9	.00060
NRG1	CAM	Neuregulin 1	5, 3	.00064
HS3ST4	ENZ	Heparan sulfate (glucosamine) 3-O-sulfotransferase 4	3, 7	.00064
MYO5B	STR	Myosin 5B	4, 11	.00065
PSD3	REC	Pleckstrin and sec7 domain containing 3	3, 15	.00078
AK5	ENZ	Adenylate kinase 5	6, 3	.00080
CUBN	REC	Cubilin	6, 6	.00085
FHIT	ENZ	Fragile histidine triad gene	8, 20	.00088

Abbreviations: Acyl-CoA, acyl coenzyme A; CAM, cell adhesion molecule; cGMP, cyclic guanine monophosphate; CHA, channels; DIS, disease associated; ENZ, enzymes; PROT, protein processing; REC, receptors (combining single TM, 7 TM, and ligand-gated channel families); RNA/DNA, RNA/DNA handling or modification; SNP, single-nucleotide polymorphism; STR, structural proteins; TF, transcriptional regulation; TRANSP, transporter.

<sup>a</sup>Each gene listed here contains at least 5 clustered positive SNPs with  $P < .05$  from sample 1 and/or sample 2, has a function that can be inferred, and displays a Monte Carlo  $P$  value  $< .001$ . Genes are grouped by the class of the function to which they appear to contribute: CAM, ENZ, STR, TF, PROT, REC, RNA/DNA, TRANSP, CHA, and DIS. The Monte Carlo  $P$  value represents probabilities of chance discovery of clustered nominally positive SNPs in segments of randomly selected genes that sum to the same size as the true gene identified in the present work. Genes listed in this Table are selected because their Monte Carlo  $P$  values are  $< .001$  and/or because they are identified in other samples in ways that are discussed in the text (see eTable [available at <http://www.archgenpsychiatry.com>] for full table, in which correction for 109 repeated comparisons would require  $P < .0004$  for significance).

<sup>b</sup>Numbers of clustered nominally positive SNPs from samples 1 and 2 that lie within the gene's exons or 10-kilobase flanks.

<sup>c</sup>Monte Carlo  $P$  value for the number of nominally significant SNPs lying within a gene region of the same size.

polysubstance abusers vs controls,<sup>32</sup> alcohol-dependent individuals vs controls,<sup>57</sup> nicotine-dependent individuals vs non-dependent smokers,<sup>58</sup> individuals successful in quitting smoking vs those unsuccessful,<sup>59</sup> and individuals with better or poorer scores in memory testing<sup>35</sup> (Table).

To provide controls for the alternative possibilities that the results obtained herein could come from (1) occult racial/ethnic stratification or (2) assay noise, we compared the clustered positive SNPs from sample 1 and from sample 2 with SNPs that displayed the largest allele frequency differences between (1) European American vs African American control individuals, as previously described<sup>32</sup>; (2) HapMap Japanese (JPT) and Han Chinese (HCB) samples; and (3) SNPs that displayed the largest variances from array to array, as previously described.<sup>32</sup>

To assess the statistical power of our analysis, we used the program PS version 2.1.31<sup>60</sup> with (1)  $\alpha = .05$ , (2) sample sizes equal to the numbers of pools from the current data set, (3) mean abuser-control differences of 0.05 and 0.1, and (4) standard deviations from the SNPs that provided the largest differences between control and abuser population means from the current data set. We also present data from the Genetic Power Calculator.

### Power Calculations

There is no single standard for calculation of the power of GWA; we have thus presented calculations based on allele frequency differences in the body of this article. An alternative approach,

the Genetic Power Calculator, assumes substantial additional information about the genetic architecture and marker frequencies for the disorder being studied and is adapted to use with allele frequency information from individual genotyping. Using a reasonable set of assumptions about the genetic architecture and linkage disequilibrium between markers and disease alleles, we obtained powers of 0.63 and 0.4 for samples 1 and 2 from this approach.<sup>61</sup>

#### Alternative Means for Analyzing GWA Data

The experiments presented herein compare (1) disease/nondisease pools (a group factor); (2) multiple case and control pools (a within-disease group factor); (3) for each pool, multiple chip assays (a within-pool factor); and (4) sample 1 vs sample 2 results. While there is no single consensus for how to treat issues raised by so many multiple comparisons, there is also no reason to assume that there is such underlying normality of the data that parametric tests, or tests that make assumptions about underlying distributions of the data (eg, analysis of variance), should be used. Monte Carlo approaches used herein provide empirical statistical values that are based on the data sets that are actually generated in these experiments and provide tests for most of the hypotheses. In previous work, these results have correlated reasonably well with those from permutation and false discovery rate tests.<sup>32</sup>

#### Use of Detailed Linkage Disequilibrium Data From HapMap Samples as a Proxy for the Detailed Linkage Disequilibrium for the Present Samples

While general patterns of linkage disequilibrium are readily inferred from HapMap data, the detailed patterns of linkage disequilibrium from a number of samples that we have previously investigated have differed, often significantly, from those in HapMap samples. Use of HapMap data as a primary basis for calculation of linkage disequilibrium in the present samples complicates the Monte Carlo simulation paradigms that we used. We have thus used chromosomal distances as a primary metric in ways that allow crisp Monte Carlo simulations for the SNPs that are well localized and eliminated data from SNPs that are not well localized.

## RESULTS

A number of features of the genotyping data support the validity of the approach used herein.<sup>32</sup> From sample 1, 371 820 SNPs (of 489 922 on 2 array types) and, from sample 2, 466 614 SNPs (of 609 431 on 4 array types) lie on chromosomes 1 to 22 and displayed minor allele frequencies of 0.02 or less. In the data from samples 1 and 2, 368 811 SNPs overlapped. Pooled genotyping for these SNPs displays features that support modest variability. Mean SEMs for the differences among the 4 replicate measurements of each DNA pool were  $\pm 0.040$  and  $0.038$  for samples 1 and 2. The SEMs for pool-to-pool differences were  $\pm 0.025$  and  $0.029$ . Power calculations that used the observed variability from these samples,  $\alpha = .05$ , and the observed within-group standard deviations document 0.92 and 1 and 0.7 and 0.99 power to detect 5% and 10% differences in mean abuser vs control allele frequencies in samples 1 and 2, respectively.

A number of SNPs displayed nominally significant allele frequency differences between methamphetamine-


dependent vs control individuals. In samples 1 and 2, 15 565 and 25 538 SNPs displayed  $t$  values with  $P < .05$  (Figure). We term these SNPs *nominally positive SNPs*; since these  $P$  values are not corrected for multiple comparisons, these data do not allow us to distinguish these values from chance.

We obtained results that differed from those expected by chance; however, when we evaluated the extent to which 3 or more of these nominally positive SNPs "cluster" together with 25 kb or more separating them, 846 clusters contained 3749 of the 15 569 nominally positive SNPs from sample 1 and 1787 clusters contained 8388 of the 25 538 nominally positive SNPs from sample 2. Such clustering is found in no Monte Carlo trial of how frequently randomly selected sets of either 15 565 SNPs from sample 1 or 25 538 SNPs from sample 2 lie clustered within 25 kb of each other. With correction for the multiple comparisons made herein, the empirical  $P$  value for clustering of nominally positive SNPs is thus  $< .00001$  for both samples 1 and 2. This degree of clustering within each single sample provides a control for the fact that we identified bona fide haplotypes that occur at different frequencies in the pools constructed from methamphetamine-dependent vs control samples. Stochastic differences in the frequencies at which these haplotypes occurred in our methamphetamine-dependent vs control samples that are independent of the addiction phenotype could conceivably contribute to some of the clustering in each individual sample, however.

We obtained evidence for replication and results that could not be expected by chance alone when we evaluated the genes that were identified by clustered nominally positive results from both sample 1 and sample 2 (Table and eTable, available at <http://www.archgenpsychiatry.com>). The degree of convergent identification of genes by data from each of these 2 samples was never observed by chance in any of 100 000 Monte Carlo simulation trials ( $P < .00001$ ). The clustering of positive results in the same genes in both samples is thus very unlikely to represent stochastic effects. We term the genes identified in 2 samples in this way "methamphetamine dependence" genes. We use this term in quotation marks because variants in at least some of these genes are also likely to alter vulnerabilities to addictions for other substances (see later). The Monte Carlo  $P$  values assigned to each gene in the Table identify the probabilities that random segments of genes that have the same size as the true gene identified in each of these 2 samples would display at least the numbers of nominally positive SNPs actually identified in the true gene (see correction for multiple comparisons in the Table legend).

These "methamphetamine dependence" genes displayed convergence with genes identified by (1) clustered positive results from 639 000 SNP GWA studies of polysubstance abuse in National Institute on Drug Abuse European American and African American samples,<sup>32</sup> (2) nominally positive SNPs from 100 000 GWA studies of alcohol dependence,<sup>57,58</sup> and (3) nominally positive SNPs in comparisons of nicotine-dependent vs nondependent smokers (Table).<sup>58</sup> Data from samples 1 and 2 converge with these previously reported data sets, with Monte Carlo  $P$  values of (1) .0412, (2) .0016, and (3) .0003, re-





**Figure.** Cartoons of chromosomes 1 to 22. The blue squares to the left of the axis represent *t* values for the methamphetamine-dependent vs control allele frequency ratios mapped to the chromosomal position of each corresponding single-nucleotide polymorphism (SNP). The SNPs for which abuser-control differences display *P* values >.05 and that pass the clustering criteria of 3 outlier SNPs from 2 array types with less than a 25-kilobase inter-SNP distance are marked with red dots to the right of the axis. Clustered SNPs in genes with convergent evidence from both sample 1 and sample 2 are marked by yellow triangles to the right of the axis. The scale bar represents 50 Mb, with chromosomal positions based on National Center for Biotechnology Information (Bethesda, Maryland) MAPVIEWER coordinates and supplemental data from NetAffix. The chromosomes are ordered in rows from left to right by chromosome number.

spectively. These analyses both correct for the multiple comparisons made and provide substantial additional support for many of the genes identified herein.

A number of the reproducibly positive genes identified in the current study are also identified by clustered positive results from 500 000 GWA studies of European American smokers who were successful vs unsuccessful in abstaining from smoking during clinical trials for smoking cessation ( $P = .002^{59}$  and  $P < .00001$  [G.R.U., unpublished data, 2007]).

The large differences between these observed results and chance clustering makes it highly unlikely that most of the clustered positive SNPs resulted from misgenotyping, for which there should be no reason that results should cluster. The SNPs that displayed clustered positive results in the current study failed to overlap appreciably more than expected by chance with the SNPs that displayed the large

est variances from array to array (391 SNPs identified vs 386 expected by chance). Many of the positive SNPs in this report were thus likely to cluster since they lie near and display linkage disequilibrium with functional variants that contribute to individual differences in vulnerability to methamphetamine dependence. Convergence with observations made in other samples supports this idea and suggests that some of the functional variants that were identified by these clustered positive SNPs are likely to contribute to vulnerability to addictions to other substances as well as to methamphetamine.

There is also no evidence that most of the SNPs identified herein were found because of occult racial/ethnic stratification between methamphetamine-dependent and control groups. There was no significant overlap between clustered reproducibly positive SNPs from samples 1 and 2 with the SNPs that provided the largest racial/

ethnic differences from comparisons between European American and African American controls or between Japanese and Chinese HapMap samples (though 523 and 737 of the outlier SNPs from samples 1 and 2 do lie in the top 2.5% of the SNPs that distinguish JPT [Japanese from Tokyo] from CHB [Han Chinese from Beijing] HapMap samples, when 389 and 532 would be expected by chance;  $.06 > P > .05$ ).

## COMMENT

This report identifies chromosomal regions that are likely to contain allelic variants that alter vulnerability to methamphetamine dependence. The validity of these observations is supported by the clustering of nominally positive SNPs and from the convergence of data from 2 independent samples. The clustered positive markers from this work identify "methamphetamine dependence" genes whose products are involved in cell adhesion, enzymatic, transcriptional regulation, and other processes. The classes of genes identified and convergence with results from other GWA studies point toward substantial roles for individual differences in mnemonic, as well as rewarding, brain systems and individual differences in vulnerability to methamphetamine dependence.<sup>20</sup>

The reliability and validity of the current approach are supported by many lines of evidence. These include data for clinical assessments made by multiple observers, the reliability and validity of the microarray-based genotyping approaches used herein,<sup>32,52,57,62</sup> the extent to which the markers that displayed nominally positive differences between abusers and controls clustered together in specific chromosomal regions, the extent to which observations made in these 2 samples converge with each other, and the extent to which these results converge with those from other studies that compare dependent vs control individuals. We have also confirmed many of the results from these approaches using individual genotyping (A. Hishimoto, MD, PhD, T.D., and G.R.U., unpublished data, 2007).

Modeling studies indicate that the experimental designs used herein have significant statistical power to detect modest differences in allelic frequencies between methamphetamine-dependent individuals and controls. Nonetheless, there remains the likelihood of both false-positive and false-negative results. Power calculations indicate that our current approach will fail to identify 1% and 38% of the alleles that actually have 10% and 5% abuser vs control differences, respectively, in both samples; other calculations support higher false-negative rates (see "Power Calculations" subsection). As always, larger samples would help to reduce these false-negative results. However, independent of the separate statistical considerations for each population studied herein, the degree of replication and convergence between the 2 samples and with other drug-abusing populations provides additional confidence in results obtained.

Monte Carlo analyses indicate that we never, by chance, could identify a group of SNPs as large as the group in the Table that (1) display nominally significant *P* values, (2) cluster together in groups of 3 or more within small chromosomal regions, and (3) provide replication

so that clustered nominally positive SNPs from comparisons in sample 1 fit with the clustered nominally positive SNPs in comparisons from sample 2. These statistical arguments are buttressed by technical convergence. Each of the clusters of nominally positive SNPs identified herein contain positive SNPs that are independently identified on at least 2 array types, each determined in quadruplicate.

In addition to the overall statistical confidence in the set of the genes identified herein, a number of these "methamphetamine dependence" genes overlap with genes identified in other GWA studies of addiction vulnerability and related phenotypes. More than half of the 23 cell adhesion genes identified in the current work are identified by prior GWA studies of polysubstance and alcohol dependence (8 genes), nicotine dependence (1 gene), memory (1 gene), and/or smoking cessation success (4 genes) in samples collected in the United States and Australia from individuals of self-reported European and African ancestries. Clustered positive markers in *DAB1* thus also distinguish those successful in quitting smoking vs those unsuccessful; *CLSTN2* (OMIM \*611323) markers also identify success in quitting smoking and individual differences in memory; *NRXN1* markers also identify vulnerability to nicotine dependence among smokers; markers in *CRIM1*, *CSMD1*, *SGCZ*, *PTPRD*, and *LRRN6C* identify vulnerability to polysubstance use and to alcohol dependence; and markers in *CDH13* (OMIM \*601364) and *DSCAM* (OMIM \*602523) identify vulnerability to polysubstance use, alcohol dependence, and success in quitting smoking. These molecules join neurexin 3,<sup>52,63</sup> *NrcAM*,<sup>64</sup> and *PTPRB* (H. Ishiguro, MD, PhD, and G.R.U., unpublished data, 2007) and other cell adhesion molecule genes that display addict vs control associations in at least 3 different samples. Such results support careful use of "methamphetamine dependence" genes to describe genes likely to contain variants that predispose to methamphetamine dependence rather than to describe gene variants that predispose to vulnerability to only this drug.

Enzyme genes that are identified herein and also by repeated substance abuse GWA studies include *DAF/CD55*, *FHIT*, *PDE4D*, and *PRKG1* (OMIM \*176894). The putative transcription factor *ZNF423* is also identified by comparisons between those successful and unsuccessful in smoking cessation.

The channel gene *RYR3*, the transporter gene *XKR4*, the gene for RNA processing *A2BP1* (OMIM \*605104), and the structural genes *ELMO1*, *SORCS1*, and *TACC2* are also identified by clustered positive results from repeated comparisons between substance-dependent and control samples. Markers at *A2BP1* also distinguish smokers who are successful vs unsuccessful in quitting.

The genes that contain markers whose frequencies distinguish the methamphetamine-dependent vs control subjects in the present report and also distinguish dependent vs nondependent subjects and those successful vs unsuccessful in quitting smoking represent an especially interesting group. These genes include *CDH13*, *DSCAM*, *PRKG1*, and *A2BP1*. Cadherin 13 is a glycosyl phosphatidylinositol-anchored cell adhesion molecule that is expressed in neurons in brain regions that are known to have a role in addiction, including the hippo-

campus, frontal cortex, and ventral midbrain.<sup>65</sup> *CDH13* can inhibit neurite extension from select neuron populations<sup>65,66</sup> and activate a number of signaling pathways.<sup>67-70</sup> It is thus a strong candidate for roles in brain mechanisms important for both developing and quitting addictions.

*DSCAM* is a single transmembrane domain cell adhesion molecule with immunoglobulin and fibronectin domains that is expressed strongly in the brain<sup>71,72</sup> and hippocampus in ways that are required for appropriate neuronal connections to form in memory-associated circuits in model organisms.<sup>73,74</sup> Flies with altered *Dscam* expression display alterations in memories of both rewarded and punished behaviors.<sup>74</sup>

*PRKG1* is expressed in the brain and hippocampus and other neurons.<sup>75,76</sup> Nitric oxide dramatically modulates brain cyclic guanine monophosphate systems; *PRKG1* thus provides a major target for the products of nitric oxide synthases. Mnemonic and addictive functions can each be altered by changes in cyclic guanine monophosphate-dependent protein kinase and/or nitric oxide synthases.<sup>77-79</sup>

The *A2BP1* gene is highly expressed in neurons in brain regions that include the hippocampus.<sup>80</sup> *A2BP1* binds to a UGCAUG splicing enhancer element found 3' to a substantial number of neuron-specific exons and thus acts as a specific regulator of the splicing processes that form mature messenger RNAs.<sup>81</sup> *A2BP1* itself contains a number of splicing variants that are likely to alter its functions.

Identifying *CLSTN2* markers in the present repeated comparisons between methamphetamine-dependent vs control subjects in repeated comparisons of success in quitting smoking and in relation to individual differences in memory is also interesting. *CLSTN2* is well positioned to provide calcium-dependent cell-adhesion functions in brain regions that include the hippocampus and in the postsynaptic densities where it is highly expressed. The identification of this and other genes whose variants are good candidates to contribute to mnemonic aspects of addiction support the view that substantial components of the individual difference in vulnerability to dependence on addictive substances relate to individual differences in mnemonic systems.<sup>20</sup>

The convergence between the genes identified by these samples and by genes identified in previous GWA studies for dependence on other legal and illegal addictive substances supports roles for allelic variants that are well represented in chromosomes from African, European, and Asian racial/ethnic groups.<sup>32,57</sup> Genes identified by these methamphetamine-dependence studies, but not as strongly by any of these other GWA comparisons, are also of interest. Neuregulin 1 is a strong candidate gene for vulnerability to schizophrenia in Icelandic and related populations.<sup>82-84</sup> Conceivably, variants in neuregulin 1 might even provide a generalized vulnerability to psychosis that could manifest itself in the presence of either methamphetamine or other risk factors for schizophrenia.

It is important to consider limitations of this convergent replicated GWA data for methamphetamine dependence. (1) The sample sizes available for this work provide moderate power to detect gene variants related to methamphetamine dependence in each sample. False-negative results are likely since we required positive data

from each of the 2 samples. The likelihood of false negatives is also increased since we required positive results from several SNPs from at least 2 array types that cluster within small chromosomal regions, making it easier to miss modest association signals within small genes that contain few SNPs or genes whose SNPs lie on only 1 array type. (2) We focused only on data from autosomal regions herein. This focus allowed us to combine data from male and female subjects but may have neglected potentially important contributions from genes on sex chromosomes. (3) Differences in allele frequencies in different populations could explain why some genes were strongly associated with methamphetamine dependence in the Asian samples studied herein but not as strongly with related substance-dependence phenotypes studied in European American or African American samples. (4) Many of the subjects for this work came to clinical attention because of methamphetamine psychosis. They might thus not be totally representative of all methamphetamine-dependent individuals. (5) While each of these individuals was methamphetamine dependent, many also reported use of additional addictive substances, such as inhalants. These clinical considerations, as well as the overlap between the "methamphetamine dependence" genes identified herein and the genes identified in other GWA work, support the idea that many, but not all, of these loci are likely to contain allelic variants that provide a more general vulnerability to addictive substances. While we term these genes "*methamphetamine dependence*" genes to denote the fact that variants in these genes are likely to alter vulnerability to developing dependence on this substance, we use the term in quotation marks to denote the probability that many of these allelic variants may predispose individuals to dependence on other addictive substances as well. (6) None of the controls for this study reported any significant use of methamphetamine. The genes identified herein thus could influence vulnerabilities to initiation of methamphetamine use, persistence of this use, and/or the transition from persistent use to methamphetamine dependence. (7) The current report uses only one of a number of current approaches to analysis of data from GWA. Additional discussion of the limits of techniques for identifying polygenic influences in complex disorders and traits can be found elsewhere.<sup>85-87</sup> Despite these cautions, however, the replicated positive results that we document herein and the failure of control experiments to support alternative hypotheses do provide substantial confidence in roles for most of the genes reported.

The current data, and results of classic genetic studies, thus support polygenic influences on vulnerability to methamphetamine dependence from genes that, as a group, are highly unlikely to represent chance observations. *P* values for individual genes, based on the data from the current work, suggest that some of these genes are very strongly supported and some more modestly supported by these current data. Genes identified by both the current results and by data from other related reports appear especially worthy of further evaluation. Taken together, the data point toward the likelihood that brains of individuals who are most vulnerable to this addiction are likely to differ in a number of ways from those of in-

dividuals who are least vulnerable. Understanding these differences in increasing detail should aid us in improving understanding, prevention, and treatments for methamphetamine dependence.

Submitted for Publication: May 8, 2007; final revision received September 14, 2007; accepted September 17, 2007.

**Author Affiliations:** Molecular Neurobiology Branch, National Institutes of Health Intramural Program, Department of Health and Human Services, Baltimore, Maryland (Drs Uhl, Drgon, and Q-R. Liu and Mss Johnson and Walther); Division of Psychiatry, National Center Hospital for Mental, Nervous, and Muscular Disorders, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Komiyama); Department of Neuropsychiatry, Kurume University School of Medicine, Kurume, Japan (Dr Harano); Department of Psychiatry and Neurology, Hamamatsu University School of Medicine, Hamamatsu, Japan (Dr Sekine); Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan (Drs Inada and Ozaki); Department of Psychiatry, Teikyo University School of Medicine, Chiba Medical Center (Dr Inada), and Department of Psychiatry, Graduate School of Medicine, Chiba University (Dr Iyo), Chiba, Japan; Department of Psychiatry, Fujita Health University School of Medicine, Aichi, Japan (Dr Iwata); Department of Psychiatry, Showa University Northern Yokohama Hospital, Yokohama, Japan (Dr Yamada); Department of Biological Psychiatry, Tohoku University Graduate School of Medicine, Sendai, Japan (Dr Sora); Japanese Genetics Initiative on Drug Abuse (Drs Komiyama, Harano, Sekine, Inada, Ozaki, Iyo, Iwata, Yamada, Sora and Ujike); Department of Psychiatry, Chang Gung Memorial Hospital, Keelung, Taiwan (Dr Chen); Department of Psychiatry, Taipei City Hospital, and Taipei City Psychiatric Center, Taipei, Taiwan, Republic of China (Drs H-C. Liu and Lin); Department of Neuropsychiatry, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan (Dr Ujike).

**Correspondence:** George R. Uhl, MD, PhD, Molecular Neurobiology, 333 Cassell Dr, Ste 3510, Baltimore, MD 21224 (guhlin@intra.nida.nih.gov).

**Financial Disclosure:** None reported.

**Funding/Support:** Financial support was received from National Institutes of Health Intramural Program (National Institute on Drug Abuse), Department of Health and Human Services, and the Taiwanese and Japanese Ministries for Science and Technology and the participating Japanese and Taiwanese institutions.

**Additional Information:** The eTable is available at <http://www.archgenpsychiatry.com>.

**Additional Contributions:** We acknowledge the invaluable assistance of the subjects and their families.

## REFERENCES

1. Uhl GR. Molecular genetic underpinnings of human substance abuse vulnerability: likely contributions to understanding addiction as a mnemonic process. *Neuropharmacology*. 2004;47(suppl 1):140-147.
2. Uhl GR. Molecular genetics of substance abuse vulnerability: remarkable recent convergence of genome scan results. *Ann N Y Acad Sci*. 2004;1025:1-13.
3. Uhl GR, Drgon T, Johnson C, Fatusin OO, Liu QR, Contoreggi C, Li CY, Buck K, Crabbe J. Higher order addiction molecular genetics: convergent data from genome-wide association in humans and mice [published online ahead of print July 25, 2007]. *Biochem Pharmacol*. 2008;75(1):98-111.
4. Uhl GR, Elmer GI, Labuda MC, Pickens RW. Genetic influences in drug abuse. In: Gloom FE, Kupfer DJ, eds. *Psychopharmacology: The Fourth Generation of Progress*. New York, NY: Raven Press; 1995:1793-2783.
5. Uhl GR, Gold LH, Risch N. Genetic analyses of complex behavioral disorders. *Proc Natl Acad Sci U S A*. 1997;94(7):2785-2786.
6. Uhl GR. Molecular genetics of substance abuse vulnerability: a current approach. *Neuropsychopharmacology*. 1999;20(1):3-9.
7. Cadoret RJ, Troughton E, O'Gorman TW, Heywood E. An adoption study of genetic and environmental factors in drug abuse. *Arch Gen Psychiatry*. 1986;43(12):1131-1136.
8. Cadoret RJ, Yates WR, Troughton E, Woodworth G, Stewart MA. Adoption study demonstrating two genetic pathways to drug abuse. *Arch Gen Psychiatry*. 1995;52(1):42-52.
9. Goldberg J, Henderson WG, Eisen SA, True W, Ramakrishnan V, Lyons MJ, Tsuang MT. A strategy for assembling samples of adult twin pairs in the United States. *Stat Med*. 1993;12(18):1693-1702.
10. Grove WM, Eckert ED, Heston L, Bouchard TJ Jr, Segal N, Lykken DT. Heritability of substance abuse and antisocial behavior: a study of monozygotic twins reared apart. *Biol Psychiatry*. 1990;27(12):1293-1304.
11. Gynther LM, Carey G, Gottesman II, Vogler GP. A twin study of non-alcohol substance abuse. *Psychiatry Res*. 1995;56(3):213-220.
12. Tsuang MT, Lyons MJ, Eisen SA, Goldberg J, True W, Lin N, Meyer JM, Toomey R, Faraone SV, Eaves L. Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. *Am J Med Genet*. 1996;67(5):473-477.
13. Tsuang MT, Lyons MJ, Meyer JM, Doyle T, Eisen SA, Goldberg J, True W, Lin N, Toomey R, Eaves L. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. *Arch Gen Psychiatry*. 1998;55(11):967-972.
14. Karkowski LM, Prescott CA, Kendler KS. Multivariate assessment of factors influencing illicit substance use in twins from female-female pairs. *Am J Med Genet*. 2000;96(5):665-670.
15. Kendler KS, Prescott CA. Cocaine use, abuse and dependence in a population-based sample of female twins. *Br J Psychiatry*. 1998;173:345-350.
16. Kendler KS, Karkowski LM, Corey LA, Prescott CA, Neale MC. Genetic and environmental risk factors in the aetiology of illicit drug initiation and subsequent misuse in women. *Br J Psychiatry*. 1999;175:351-356.
17. Woodward CE, Maes HH, Silberg JL, Meyer JM, Eaves LJ. Tobacco, alcohol and drug use in 8-16 year old twins. *NIDA Res Monogr*. 1996;162:309.
18. Merikangas KR, Stolar M, Stevens DE, Goulet J, Preisig MA, Fenton B, Zhang H, O'Malley SS, Rounsaville BJ. Familial transmission of substance use disorders. *Arch Gen Psychiatry*. 1998;55(11):973-979.
19. True WR, Heath AC, Scherrer JF, Xian H, Lin N, Eisen SA, Lyons MJ, Goldberg J, Tsuang MT. Interrelationship of genetic and environmental influences on conduct disorder and alcohol and marijuana dependence symptoms. *Am J Med Genet*. 1999;88(4):391-397.
20. Uhl GR. Molecular genetics of addiction vulnerability. *NeuroRx*. 2006;3(3):295-301.
21. Cervino AC, Hill AV. Comparison of tests for association and linkage in incomplete families. *Am J Hum Genet*. 2000;67(1):120-132.
22. Sham PC, Cherny SS, Purcell S, Hewitt JK. Power of linkage versus association analysis of quantitative traits, by use of variance-components models, for sibship data. *Am J Hum Genet*. 2000;66(5):1616-1630.
23. Risch N, Merikangas K. The future of genetic studies of complex human diseases. *Science*. 1996;273(5281):1516-1517.
24. Schork NJ, Nath SK, Fallin D, Chakravarti A. Linkage disequilibrium analysis of biallelic DNA markers, human quantitative trait loci, and threshold-defined case and control subjects. *Am J Hum Genet*. 2000;67(5):1208-1218.
25. Barcellos LF, Klitz W, Field LL, Tobias R, Bowcock AM, Wilson R, Nelson MP, Nagatomi J, Thomson G. Association mapping of disease loci, by use of a pooled DNA genomic screen. *Am J Hum Genet*. 1997;61(3):734-747.
26. Germer S, Holland MJ, Higuchi R. High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR. *Genome Res*. 2000;10(2):258-266.
27. Hacia JG, Fan JB, Ryder O, Jin L, Edgemon K, Ghandour G, Mayer RA, Sun B, Hsie L, Robbins CM, Brody LC, Wang D, Lander ES, Lipshutz R, Fodor SP, Collins FS. Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays. *Nat Genet*. 1999;22(2):164-167.
28. Uhl GR, Liu QR, Walther D, Hess J, Naiman D. Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. *Am J Hum Genet*. 2001;69(6):1290-1300.